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Cystic fibrosis (CF) is an inherited disorder that affects over 30,000 people in the 
US and more than 70,000 people worldwide. Recurring bacterial infections in CF patients 
result in tissue damage that dramatically lowers respiratory function and are ultimately 
fatal. The formation of bacterial biofilms in the mucus and on lung epithelial tissue 
allows pathogens to be protected from antibiotics and the host immune system, making 
treatment of infection difficult. The interactions between CF pathogens in co-culture 
biofilms are not well understood and were examined in this study. Staphylococcus aureus 
and Burkholderia cenocepacia, two common CF pathogens, were used to examine the 
effects of co-culture on biofilm formation. We found that S. aureus biofilm formation and 
maintenance is inhibited when grown in co-culture with B. cenocepacia. In fact, 
supernatant from 3-day-old biofilms of B. cenocepacia was sufficient to reduce S. aureus 
biofilms, suggesting that a secreted compound may be responsible for this antagonism.  
The results of this study can be used to better understand the complex microenvironments 
bacteria experience in CF lungs. Further exploration of this interaction could lead to 




Cystic fibrosis (CF) is a recessive genetic disorder most common to Caucasians, a 
population in America in which 1 out of every 29 individuals is a carrier for a CF allele 
[1]. This disease is inherited by obtaining two copies of a mutant CFTR gene, which 
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normally encodes an ion channel in the cell membrane called the cystic fibrosis 
transmembrane conductance regulator (CFTR). Both chloride and bicarbonate ions have 
been shown to utilize this protein to exit the cell, and they contribute to the maintenance 
of salt balance and mucin dissolution for healthy exocrine mucosal secretions [2].  
Many different CFTR mutations can lead to a mutant phenotype [3], which can 
consist of either the absence or dysfunction of the CFTR channel. Due to CFTR defects, 
CF patients have a lowered ability or incapacity to transport chloride and bicarbonate 
anions outside of the cell [4]. The resulting ion imbalance causes dehydration of the 
mucus outside of the cell, hindering mucociliary clearance and making clearance through 
coughing arduous [5]. The altered mucus can affect the antimicrobial function of 
defensins, lysozymes, and other host pathogen-targeting compounds [5-7]. The mucus 
inside the lumen is rich in carbon and other nutrients, which can be metabolized by 
microbes [8]. Thus, the environment in the lumen of the CF lung is conducive to bacterial 
growth and infection.  
Mutations in the CFTR gene can also result in compromised cellular and immune 
function. CF lungs are in a hyper-inflammatory state due to chronic bacterial infections as 
well as the accumulation of misfolded and degraded proteins inside the cell. The cellular 
process of autophagy normally assists in removal of unwanted proteins and cytosolic 
debris through fusion of phagosomes with degradative lysosomes [9]. Defects in 
autophagy have been observed in CF-derived cell lines and have been shown to lead to 
increased inflammation in the lung airways [10-12].  Furthermore, airway epithelial cells 
and neutrophils lacking functional CFTR proteins have altered cytokine responses 
compared to wild-type cells [13-15], suggesting a possible impairment of immune 
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responses to pathogens.  
Due to the viscosity of CF mucus, epithelial cilia are weighed down and clearance 
of microbes is severely impeded [16]. This stagnant environment can result in microbial 
growth in the mucus and allow bacteria to anchor to lung tissue. Bacteria in this 
environment can form biofilms, which are mats of bacterial cells embedded in an 
extracellular polymeric substance (EPS) made of polysaccharides, proteins, and 
extracellular DNA. EPS forms a sticky matrix that protects the enclosed bacteria from 
antibiotics, desiccation, and predation by immune cells.  
The ability of bacteria in biofilms to evade the immune system and resist even the 
strongest antibiotics contributes to chronic bacterial infections and other symptoms seen 
in CF patients [17, 18]. Neutrophil and macrophage invasion to the site of infection leads 
to inflammation, which can chronically damage host cells and lead to tissue damage [19]. 
There is a decrease in surface area for oxygen exchange in the scar tissue that develops 
from chronic inflammation [20]. Chronic infection and accumulating tissue damage over 
the course of their lives cause CF patients to experience a slow suffocation until the 
severity of lung damage leads to death.   
Even though the airway in CF patients is rife with nutrients, only some 
opportunistic bacterial pathogens succeed in this environment. The most common 
pathogens in CF patients are Staphylococcus aureus, Pseudomonas aeruginosa, 
Haemophilus influenzae, Stenotrophomonas maltophilia, and members of the 
Burkholderia cepacia complex, including Burkholderia cenocepacia [21]. Of these, S. 
aureus and P. aeruginosa are the dominant pathogens and can be annually cultured from 
80% of CF patients.  Infections by these organisms are difficult to treat due to intrinsic 
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antibiotic resistance.  In addition, these pathogens are frequently spread between patients 
nosocomially [22, 23]. Development of new therapeutics against these bacteria could 
benefit both CF patients and hospitalized individuals worldwide. 
 
Staphylococcus aureus 
 S. aureus is a Gram-positive, non-motile bacterial species first discovered in 1880 
in a skin abscess by Sir Alexander Ogsten [24].  It is estimated that 30% of the human 
population carry S. aureus as a commensal organism [25], usually in the upper 
respiratory tract, and it can be found commensally on other mammals [26-34].  The 
genome of S. aureus consists of a single 2.8 megabase pair (Mbp or 1 million base pairs) 
chromosome and contains pathogenicity islands for a variety of toxins and other 
virulence factors [34]. Plasmids and several other mobile genetic elements encode 
antibiotic resistance genes in both methicillin sensitive (MSSA) and methicillin resistant 
(MRSA) S. aureus strains.   
 As an opportunistic pathogen, S. aureus can cause a variety of infections in 
susceptible hosts. This species is the most frequent infectious agent of infective 
endocarditis [35] and osteoarticular infection [36]. This species can cause pneumonia 
[37], infection of prosthetic joints [38-39], and it can form biofilms on catheters [40], 
prosthetic heart valves [41], pacemakers [42] and other prosthetic devices [43]. Skin and 
soft tissue infections by S. aureus manifest as abscesses, cellulitis, boils, impetigo, and 
infection of wounds [44].  
As a primarily extracellular pathogen, the Microbial Surface Components 
Recognizing Adhesive Matrix Molecules (MSCRAMM) are a critical component of S. 
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aureus pathogenicity and contribute to the initial attachment to host cells [53,54]. These 
proteins are located on the surface of the cell, covalently bound to the peptidoglycan of 
the cell wall [55]. Components of S. aureus MSCRAMM include fibronectin binding 
proteins, clumping factors, and S. aureus protein A (SpA) [56-59]. Fibronectin binding 
proteins and clumping factors act as adhesins, anchoring the cells to the extracellular 
matrix of host tissue for colonization [53]. SpA is a protein unique to S. aureus and 
contains several immunoglobulin-binding domains [60]. The function of SpA is to bind 
the Fc portion of immunoglobulin G. This interaction prevents Fc from being recognized 
by – and interacting with – phagocytic neutrophils and macrophages, thereby allowing S. 
aureus to avoid detection by the circulating antibodies and evade classical complement 
formation, opsonization, and phagocytosis [61]. 
The majority of S. aureus strains produce exotoxins that function as 
superantigens, which are potent mitogens that trigger massive proliferation of T cells and 
cytokine production [45]. This immune response can overwhelm the human body and 
lead to septic shock. Enterotoxins secreted by this species and other staphylococci 
quickly cause food poisoning when consumed from undercooked, unpasteurized, or 
handler contaminated foods [46, 47]. Another S. aureus toxin, called toxic shock 
syndrome toxin, is a causative agent of toxic shock syndrome [48].  
Other toxins produced by S. aureus strains do not act as superantigens but directly 
target host cells for destruction. Leukotoxins produced and secreted by S. aureus act to 
form holes in the membrane of host leukocytes, upsetting the osmotic balance and 
resulting in cell lysis [49]. The leukotoxin γ-hemolysin targets red blood cells and can 
cause massive hemolysis [50], while the monomeric α-toxin (or α-hemolysin) is highly 
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cytotoxic and polymerizes to form a water channel in host cell membranes [51]. This 
leukotoxin leads to apoptosis through activation of a caspase cascade [52]. These 
leukotoxins extend bacterial infection by eliminating predatory immune cells and 
enhancing invasion of host tissue.  
 In addition to producing adhesins for attachment to host tissue during initial 
colonization, S. aureus also produces factors that assist in cell-to-cell binding and biofilm 
formation. The intercellular adhesin (ica) locus is found in S. aureus and several other 
staphylococcal species and encodes enzymes necessary for the production of 
polysaccharide intercellular adhesin (PIA), a component of staphylococcal EPS [62]. The 
products of the ica locus are necessary for initiation of biofilm formation by assisting in 
intercellular attachment between cells. The ability of S. aureus to form biofilm and attach 
to biomedical implants contributes to its ability to cause sepsis and recurring infection in 
host tissue.  
 Difficulty in treatment of S. aureus infection is due to the extensive range of 
antibiotics to which both MSSA and MRSA strains have evolved resistance. Over 90% of 
S. aureus isolates encode β-lactamase, eliminating certain penicillins as useful antibiotics 
[63]. While penicillinase-resistant penicillins are available, they are usually limited to 
treatment of severe MSSA infection. After its introduction in 1961, strains resistant to 
methicillin – a penicillinase-resistant penicillin – quickly surfaced [64], and MRSA 
strains have rapidly increased in prevalence of infections over the past 50 years. In the CF 
community, MRSA infection has increased from 6.1% of patients in 2000 to 26% in 2015 
[21]. 
The mecA gene in MRSA isolates is located on the staphylococcal cassette 
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chromosome mec (SCCmec) and encodes the enzyme that confers resistance to 
methicillin, penicillin, and other β-lactams [65]. The SCCmec is a mobile genetic element 
capable of horizontal gene transfer between staphylococcal strains [66]. Some studies 
suggest vancomycin is inferior to β-lactams as an antimicrobial, but it is still able to 
effectively eliminate infection of both MSSA and MRSA [67, 68]. However, strains 
bearing vancomycin resistance (VRSA) have also begun to appear in isolates of S. aureus 
[69], increasing the vital need for discovery of new anti-staphylococcal compounds and 
vaccine development for S. aureus.  
 S. aureus  is typically the first organism that colonizes the CF lung and remains 
the most common CF isolate in individuals under 25, with prevalence of S. aureus 
colonization peaking between ages 11-15 [63,70]. Rates of MRSA infection during 
childhood are substantially higher in the United States than in Europe [70].  
Approximately 25% of annual CF cultures are positive for MRSA, while the prevalence 
of MRSA in Europe remains about 5%. This indicates that MRSA is a pressing problem 




 The Burkholderia cepacia complex (Bcc) consists of 18 related Gram-negative 
species that thrive in a diverse array of environmental niches and have a broad array of 
metabolic capabilities, including nitrogen fixation [71], pollutant metabolism [72, 73], 
antifungal production [74], and plant pathogenesis [75]. These bacteria are typically 
found in the soil or water, and this versatility seen in Bcc ecological specialization is 
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attributable to their uniquely complex genomes. Most Bcc species have genomes over 
twice the size of the Escherichia coli genome [76]. Where as the majority of bacteria 
have one circular chromosome, Bcc genomes consist of two or three circular 
chromosomes and at least one large plasmid [77]. The CF isolate B. cenocepacia J2315, 
for example, has four replicons, with approximate sizes of 3.8 Mbp, 3.2 Mbp, 875 
kilobase pairs (kbp) and 92 kbp, which together encode over 7,000 predicted coding 
regions.    
The first isolation of a Bcc member from a CF patient occurred in the 1970s [78], 
and a CF epidemic in the 1980s involving B. cenocepacia increased the significance of 
the Bcc as opportunistic human pathogens [79]. Analysis of the B. cenocepacia J2315 
genome has implicated the role of horizontal gene transfer of genomic islands in the 
development of human virulence factors [77]. Currently, B. cenocepacia and B. 
multivorans are the most common Bcc species isolated from CF patients in North 
America [80] and Europe [81], respectively.  
B. cenocepacia strains found in either the environment or as clinical isolates can 
be categorized into four different subgroups [82]. Subgroup IIIA includes B. cenocepacia 
J2315 and the ET12 lineage from which it is derived. The ET12 lineage of B. 
cenocepacia caused a large epidemic in the CF community in the 1980s and 1990s [83]. 
This strain was transmitted across the United Kingdom, Canada, and Europe due to 
contact between patients. The ET12 epidemic lineage encodes a cable pilus that can assist 
in binding to both mucins [84] and host tissue [85], and isolates have been shown to 
dominate and replace infections originally caused by B. multivorans [86].  
 B. cenocepacia J2315 contains genes that confer natural resistance to several 
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antibiotics, including β-lactams, aminoglycosides, chloramphenicol, trimethoprim-
sulfamethoxazole, and gentamicin [77]. This strain also expresses type IV pili that are 
involved in motility and cellular adhesion to host tissue. Additionally, these pili have 
DNA binding activity [87] suggesting they may play a role in biofilm formation, in which 
extracellular DNA is a critical component of the secreted matrix. Like S. aureus, the 
ability of this strain to bind to both host tissue and form biofilms contributes to its 
virulence as a CF pathogen. 
The secretion systems utilized by B. cenocepacia J2315 play an important role in 
the infection of human tissue. When cells of this strain are taken up by macrophages, the 
bacteria evade degradation and survive inside an endocytic vacuole [88]. The type IV 
secretion system has been implicated in the ability of B. cenocepacia to survive 
macrophage phagocytosis by evasion of lysosomal fusion [89]. The type VI secretion 
system has been shown to reduce production of reactive oxygen species inside 
macrophages [90].  
The importance of Bcc as CF pathogens lie in their high transmissibility between 
patients and the quick progression of CF pathogenesis associated with Bcc infection [91]. 
“Cepacia syndrome” is characterized by bacteremia and a sudden rapid deterioration of 
lung function from necrotizing pneumonia [92]. The large majority of incidents of these 
symptoms occurred when CF patients were infected with a Bcc member. In addition, 
presence of Bcc is correlated with an increased risk of death in CF patients. Even with the 
dominance of S. aureus and P. aeruginosa as the most common CF pathogens, the risks 




Bacteria form biofilms as a defensive mechanism against a variety of potentially 
damaging conditions, such as presence of phagocytic predator cells, abrasive mechanical 
stimuli, or exposure to antibiotics. Initiation of biofilm formation involves quorum 
sensing, which is a method of altering gene expression at the population level based on 
cell density [93]. Initially, cells use adhesins and extracellular structures to reversibly 
attach to a surface, such as host tissue or synthetic material. During the second stage of 
biofilm formation, cells begin secreting molecules for formation of the EPS, which 
results in the irreversible attachment of bacteria to other cells and surfaces.   
After permanent attachment to a surface, biofilm cells will begin to replicate, 
resulting in formation of clusters of bacteria termed microcolonies. Replication and EPS 
production continue until a mature biofilm with a unique three-dimensional structure is 
formed. Depending on how bacteria are communicating within or between species, 
different biofilm morphologies can be observed. P. aeruginosa, one of the most well-
studied biofilm formers, typically forms globular biofilms that resemble mushrooms [94]. 
This mushroom model of biofilm morphology is a commonly observed phenotype [95].  
After biofilm maturation, the final stage of biofilm formation is the release of 
cells back to a planktonic, free-swimming lifestyle. This change involves dissolution of a 
portion of the biofilm EPS to allow cells to leave the biofilm and potentially begin the 
cycle all over again, initiating biofilm formation on another surface [96]. The biofilm 
lifestyle can increase the minimum inhibitory concentration of antibiotics 1000-fold 
[97,98] and make phagocytosis by macrophages difficult [99, 100], thus increasing the 
virulence and persistence of human bacterial pathogens inside the host.  
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Co-Culture Biofilms 
Single and polymicrobial biofilms can take on unique structures and spatial 
organizations that result in complex microenvironments [101, 102]. Different species can 
lay down in layers like stacks of paper, can arrange in a heterogeneous mixture of 
bacteria and involve contact with other species, or can remain in localized clusters with 
little to no cell-to-cell contact between microcolonies. Bacteria at the surface of a biofilm 
or in the lining of water channels will have different nutrient and oxygen availability than 
those near the bottom or the center of the biofilm. This arrangement results in unique 
metabolic states and requirements based on an organism’s location within the biofilm.   
 Co-infection by pathogens in CF lungs is a common occurrence. In one group of 
CF patients participating in a clinical trial, 43.2% of individuals that were colonized by P. 
aeruginosa were also colonized by S. aureus [103]. Of 595 patients sampled, an average 
of 2.9 strains were cultured per person, including isolates of the biofilm-forming bacteria 
P. aeruginosa [104], Achromobacter xylosoxidans [105], B. cepacia [106], S. aureus 
[107], and S. maltophilia [108]. Given co-infection of CF patients with these bacteria, the 
CF lung likely acts as an ideal environment for the formation of mixed species biofilms, 
and the combinations of different strains may result in unique symptoms and severity of 
disease.  
It is clear that a complex polymicrobial community inhabits CF lungs and that the 
microbial contents of CF airways change throughout a patient’s lifetime. Multispecies 
biofilms and CF pathogen interactions are therefore important areas of research to 
understand CF pathogenesis. Monospecies biofilms have been studied in depth, such as 
those of P. aeruginosa [93, 109, 110], but only a few studies have explored co-culture 
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biofilms of CF pathogens. For example, the co-culture biofilm of P. aeruginosa and S. 
maltophilia may act to enhance antibiotic resistance compared to single species biofilms 
[111]. Clinical isolates of B. cepacia and P. aeruginosa grown in co-culture have been 
shown to form stable mixed biofilms [112]. In another study, P. aeruginosa PAO1 
enhanced biofilm formation in S. aureus when grown in co-culture [113]. These studies 
are preliminary, and the interactions between many different CF pathogens remain to be 
explored.  Currently, there is little to no understanding of the interaction between S. 
aureus and B. cenocepacia in a multispecies biofilm. The prevalence of the former and 
the mortality of the later make interactions between the pair an interesting topic of study. 
The purpose of this study was to analyze polymicrobial interactions and biofilm 
formation in co-culture conditions of different CF pathogens. Originally, representative 
strains of five CF pathogens commonly isolated from the CF lung were tested for co-
culture biofilm formation. These pathogens included P. aeruginosa, S. aureus, B. 
cenocepacia, A. xylosoxidans, and S. maltophilia. Pairwise combinations of these species 
were grown in co-culture conditions and analyzed for biofilm formation, and the unique 
interaction between S. aureus and B. cenocepacia was chosen for further exploration. The 
data suggests that B. cenocepacia inhibits biofilm formation and maintenance of S. 
aureus. Based on these preliminary data, the main hypotheses for this study were that (1) 
S. aureus biofilm formation would be inhibited when grown in co-culture with B. 
cenocepacia J2315, (2) mature monoculter S. aureus biofilm would be diminished when 
exposed to B. cenocepacia, and (3) destruction of S. aureus biofilm in the presence of B. 
cenocepacia would occur over time. 
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Materials and Methods 
Bacterial Isolates and Materials 
 Luria Broth Lennox formulation (LB) was used to make both agar plates and 
liquid culture medium. Unless specified otherwise, all bacterial strains were plated from 
freezer stocks on LB agar plates and grown at 37C for 24-48 h. For overnight cultures, 
single colonies were inoculated into 5 mL LB and incubated at 37C with aeration until 
the next day. Plates and broth were supplemented with antibiotics as indicated. All strains 
can be found in the Yoder-Himes Lab strain collection. A complete list of all bacterial 
isolates used during the course of this project are listed and described in Table 1.  
 










CF clinical isolate - 
Bcc isolates 
A1-4 










16-171 This study 
B. cenocepacia 
J2315-301 
J2315 bearing plasmid 
pIN301 encoding GFP 
chloramphenicol 
100 
16-172 This study 
S. aureus NRS77 Blood clinical isolate - 13-012 
BEI Resources; also 
known as NCTC 8325 
or PS47 




BEI Resources; also 
known as Sanger476 
S. aureus 
AH2183 
Derivative of NRS77 - 16-082 
Dr. Alexander Horswill 
(University of Iowa) 
S. aureus 
AH3865 






Dr. Alexander Horswill 
(University of Iowa) 
S. aureus 
AH1710 
RN4220* containing a 




Dr. Alexander Horswill 
(University of Iowa) 
A. xylosoxidans 
AU19284 
CF clinical Isolate - 13-005 





Blood clinical isolate - 
HMS Bcc/Pa 
3 






CF clinical isolate; 





Dr. Stephen Lory 
(Harvard Medical 
School) 
E. coli DH5α 
pIN62 






Dr. Annette Vergunst 
(University of 
Montpelier, France) 
E. coli DH5α 
pIN301 






Dr. Annette Vergunst 
(University of 
Montpelier, France) 
E. coli DH5α 
pIN298 
DH5α containing a 





Dr. Annette Vergunst 
(University of 
Montpelier, France) 
*Restriction deficient S. aureus strain RN4220 is defective in the restriction-modification system that 
targets foreign DNA for destruction, therefore enhancing genetic manipulation of S. aureus in the lab.  
 
Biofilm Quantitation 
Choosing Material for Optimized Biofilm Formation 
 Overnight cultures of S. aureus NRS77, B. cenocepacia J2315, A. xylosoxidans 
AU19284, P. aeruginosa C3719, and S. maltophilia K279a in LB were diluted 1:100 in 
TSB, and 100 μL of each culture was added to triplicate wells of both a sterilized 96-well 
PVC plate (Costar, #29442-384) and a 96-well polystyrene plate (Greiner Bio-One, #655-
185). The PVC plate was covered with porous sealing film (VWR, #60941-086), and the 
polystyrene plate was covered with the provided lid. Both plates were incubated at 37°C 
for 24 h. Quantitation of each monoculture biofilm on both plates was completed using 
the microtiter dish biofilm formation assay published by O’Toole [114]. Absorbance was 
measured using a Tecan Sunrise plate reader with optical density at 595 nm.  
 
Co-culture Biofilm Formation Assays and Optimization 
  S. aureus NRS77, B. cenocepacia J2315, A. xylosoxidans AU19284, P. 
aeruginosa C3719, and S. maltophilia K279a were grown overnight and diluted 1:100 in 
Tryptic Soy Broth (TSB). Equal volumes of each strain were added to centrifuge tubes in 
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pairs, then vortexed for 5-6 seconds to thoroughly mix the cultures.  Two 96-well PVC 
plates were sterilized using 70% ethanol and allowed to dry in a biosafety cabinet. To 
both plates, 100 μL of mixed co-culture was added to three replicate wells. Positive 
controls consisted of triplicate wells with 100 μL of diluted single cultures. Plain TSB 
served as a negative control. The plates were sealed using porous sealing film to allow 
oxygen to freely cross, then covered with aluminum foil to help prevent desiccation. The 
plates were placed in an acrylic tub lined with damp paper towels and incubated at 37C 
for 24  or 72 h.  
 
Sonication and Drip Dilutions 
 Sonication was used to quantitate the number of cells in a biofilm using a 
procedure adapted from Harrison, et al [115]. After the 96-well plate had been incubated 
for the desired amount of time, the foil and sealing film were removed and the liquid 
culture dumped into a 10% (v/v) bleach solution. The plate was gently and briefly placed 
upside down on a paper towel to allow residual liquid to be removed from the surface of 
the plate. This step helps prevent cross contamination of the wells in the later steps of the 
procedure. Aliquots of 115 L of sterile water were added to the wells, and the samples 
were incubated for one min. The water was dumped out of the plate and 115 μL of 1% 
Tween 20 in LB was added to each well to act as the recovery medium. The plate was 
covered with sealing foil (USA Scientific, #2923-0110) and placed on the bottom level of 
a test tube rack. The rack was suspended inside an ultrasonic cleaner (Branson 3200) 
until the liquid in the wells was submerged below the level of the water in the cleaner. 
The plate was subjected to sonication at 60 Hz for 10 min to disrupt biofilms, as 
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suggested in the protocol by Harrison, et al [115].  
 The foil was wiped down with 70% ethanol to ensure it was sterilized. A pipet tip 
was use to punch through the foil and transfer 20 μL from the well to 180 μL phosphate 
buffer solution (PBS) in row A of a separate flat bottom polystyrene 96-well plate. After 
the entire row had been inoculated, 10-fold serial dilutions were performed. Using an 
eight-channel pipettor, 10 μL of the entire serial dilution were transferred to a square 
plate containing LB medium, which was set on its side and slanted to allow the drops to 
run down the agar. The drops were allowed to run three quarters of the way down the 
plate before replacing the lid and setting the plate down flat. 
 Plates were incubated at 37C for 24-48 h, or until colonies became 
distinguishable. Supplementary Table 1 shows the colony morphology and incubation 
time for each strain. Typically, S. aureus colonies were counted after 24 h, while B. 
cenocepacia colonies were counted after 48 h. Colonies were counted in the drip line that 
contained between 11-100 colonies for each specific strain, and the number of live 
bacteria per milliliter of recovery medium (colony forming units per milliliter or 
CFU/mL) was calculated using both these values and the dilution factor of the most 
appropriate dilution.   
 
Standardizing Viable Cell Count 
 To eliminate the variability in the viable cell count of overnight cultures between 
strains, drip dilutions were performed for cultures grown to an optical density at 600 nm 
(O.D.600) of 0.8, which corresponds to mid-log phase growth. Overnight cultures were 
grown by inoculation of 5 mL LB with the desired strain, followed by incubation at 37°C 
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with aeration until the next day. Overnight cultures were made for B. cenocepacia J2315, 
S. aureus NRS77, S. aureus NRS72, S. aureus AH3865, S. aureus AH2183, S. aureus 
AH1710, and S. aureus AH2547. For each strain, 100 L of the overnight culture was 
added to fresh, pre-warmed LB. These were allowed to grow at 37C with aeration until 
O.D.600 reached 0.8, and the tubes were placed on ice until all strains reached this O.D. 
The cultures were serially diluted in PBS, and then drip dilutions were performed to 
quantitate the viable cell count of each strain at O.D.600 of 0.8. 
   
Co-Culture Biofilm Assays 
Co-culture Biofilms of five CF Pathogens in Pairwise Combinations 
The methods described under the sections Co-culture Biofilm Formation Assays 
and Optimization and Sonication and Drip Dilutions were followed using all ten pairwise 
combinations of B. cenocepacia J2315, S. aureus NRS77, A. xylosoxidans AU19284, P. 
aeruginosa C3719, and S. maltophilia K279a. For each combination, equal volumes of 
cultures were added to microfuge tubes and vortexed for 5-6 seconds. Triplicate wells of 
two 96-well PVC plates received 100 μL of each mixture and plates were incubated for 1 
or 3 days. During drip dilutions, only the 103-107 dilutions were plated. Plating of 10 μL 
of this serial dilution therefore placed the limit of detection of the viable cell counts at 105 
CFU/mL. 
 
The effect of B. cenocepacia J2315 on multiple S. aureus strains 
To examine the ability of B. cenocepacia J2315 to affect various S. aureus strains, 
four S. aureus isolates were used and paired with B. cenocepacia J2315 in co-culture 
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conditions. Diluted cultures of each S. aureus strain, NRS77, NRS72, AH2183, and 
AH3865 were mixed 1:1 (v/v) with diluted B. cenocepacia J2315 culture. In addition to 
each co-culture, monocultures were also inoculated in triplicate wells of three different 
96-well PVC plates, which were incubated for 1, 3, or 7 days. Wells containing TSB 
acted as the negative control. The procedure for the co-culture biofilm formation assay, 
with sonication and drip dilutions, was followed for this experiment.  
 
Inoculation of Pre-established S. aureus NRS77 Biofilms with B. cenocepacia J2315  
S. aureus NRS77 was grown to an O.D.600 of 0.8, then diluted 1:10 in TSB. In a 
sterilized 96-well PVC plate, 100 μL of the culture was added to 10 sets of triplicate 
wells. Another set of wells was inoculated with TSB as a negative control. The plate was 
sealed with porous film, covered with aluminum foil, and placed in an acrylic bin lined 
with damp paper towels. After covering the bin with plastic wrap, the bin was placed in a 
37C room for 72 h. Water was added to the bin daily to prevent desiccation of the 
biofilms.  
The same day that the S. aureus monoculture biofilm plate was to be removed, B. 
cenocepacia J2315 and S. aureus NRS77 cultures were grown to an O.D.600 of 0.8 then 
diluted 1:100 or 1:10 in TSB, respectively, in a microfuge tube. Based on the results from 
the Standardizing Viable Cell Count experiment in the section above, the dilutions of 
both strains had approximately the same cell count. Three different cultures were then 
made from these dilutions: B. cenocepacia J2315 monoculture, S. aureus NRS77 
monoculture, and co-culture of B. cenocepacia J2315 and S. aureus NRS77. In addition 
to equalizing the cell count between strains, the total cell count of each strain must be the 
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same in the co-culture condition as in the single culture condition. This feat was 
accomplished by aliquoting 1 mL of diluted B. cenocepacia J2315 culture into a 
microfuge tube, centrifugation of the cells for one min at 21,130 x g, pouring off the 
supernatant, then resuspending the pellet in 1 mL of the diluted S. aureus NRS77 culture. 
All microfuge tubes were vortexed for 6 seconds to homogenize the mixtures. 
The covers from the established S. aureus biofilms were removed and the biofilm 
supernatant was poured into a bleach solution. After dabbing off excess liquid from the 
surface of the plate, 100 μL of diluted S. aureus NRS77 was added to three sets of 
triplicate wells, one set each for day 1, 3 and 7. This step was repeated for the culture of 
diluted B. cenocepacia and the co-culture mixture. In addition, 100 μL of diluted B. 
cenocepacia was added to three triplicate non-biofilm containing wells to act as a 
positive control for biofilm formation at the point of inoculation. TSB was used as a 
negative control. 
At this point, 9 sets of the triplicate S. aureus NRS77 biofilm wells were 
inoculated with either experimental or control treatments. The tenth set of S. aureus 
biofilm wells and the negative control from initial S. aureus inoculation were washed 
with 115 μL sterile water then scraped into 115 μL of 1% Tween 20 recovery medium 
using a P200 pipette tip.  The medium was pipetted out of the wells, serially diluted, and 
plated for drip dilutions to determine the starting CFU/mL of the S. aureus biofilm at the 
point of B. cenocepacia inoculation.  
The biofilms were once again covered with porous sealing film and aluminum 
foil, and then placed on damp paper towels in an acrylic, plastic-wrap-covered bin.  The 
plate was incubated for 1, 3, and 7 days. On each day, the plate was uncovered, the liquid 
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culture of the wells of interest were removed with a pipette, and the wells were washed 
with sterile water, as described above. Because wells containing conditions for 1, 3, and 7 
day biofilm formation were all on the same plate, biofilms were disrupted by scraping 
with a 200 μL pipette tip, instead of through sonication. Biofilms were quantitated using 
drip dilutions. The plate was covered and incubated at 37C between time points. On the 
final day, the negative control was also plated.  
 
Fractionating B. cenocepacia J2315 cultures 
 B. cenocepacia J2315 cultures were separated into the supernatant and cellular 
components.  Supernatant was isolated in two ways. First, B. cenocepacia J2315 was 
grown in a biofilm for three days in 64 wells of a 96-well PVC plate, as described above 
for the growth of monoculture S. aureus biofilm. On day three, the liquid from each well 
was removed and added to a microfuge tube. The cells were pelleted at 21,130 x g in a 
microfuge for one min, and the supernatant was filter-sterilized through a 0.45 m 
syringe filter. Aliquots of this sterilized supernatant were plated to ensure no viable B. 
cenocepacia J2315 cells remained.  The total volume of collected supernatant was 
approximately 6.4 mL. To this, 6.4 mL of 20% glycerol in LB was added to result in a 
10% glycerol solution that could be stored at -20°C until use.  
Overnight culture supernatant was also isolated. B. cenocepacia J2315 was grown 
overnight in LB, centrifuged at 21,130 x g for one min, and the supernatant was filter-
sterilized. Each supernatant solution was added 1:1 (v/v) with TSB and added to S. 
aureus biofilm to yield a 25% biofilm supernatant treatment and a 50% overnight 
supernatant treatment, both with 50% TSB. Additionally, the pellet formed after the 
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centrifugation of the overnight B. cenocepacia J2315 culture was resuspended and diluted 
1:100 in TSB before addition to S. aureus biofilms.  
 
Sonication of B. cenocepacia J2315 cells and biofilm assay 
To determine if live cells were needed for the toxic effect on S. aureus, dead B. 
cenocepacia cells were made by placing an overnight culture of the J2315 strain in a 
65°C water bath for 30 min then sonicated at 60% amplitude for 10 second pulses over a 
period of 10 min in a Qsonica cup sonicator (Qsonica, Q800R). This culture was not 
diluted, but mixed with TSB in a 1:1 (v/v) ratio. Plating of serial dilutions of the resulting 
culture showed no viable cells remained after sonication. 
 Live cells, sonicated cells, or either supernatants were added to triplicate wells 
containing one-day old S. aureus biofilms and also to empty wells to act as controls. One 
set of triplicate wells containing S. aureus biofilm received 100 μL plain TSB to act as a 
control for S. aureus biofilm formation. Another set of empty wells received TSB as a 
negative control. Two PVC plates were made with these conditions, and one was 
incubated at 37C for 24 h, while the second was incubated for 72 h. The protocol 
described above in Sonication and Drip Dilution Biofilm was used to quantitate biofilm 
formation.  
 
Phenotypes of Co-culture Biofilms 
Super Optimal Broth Preparation for B. cenocepacia Transformation 
 Super optimal broth (SOB) and super optimal broth with catabolite repression 
(SOC) are media used to promote higher plasmid transformation efficiency in bacteria. 
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To make SOB, 20 g tryptone, 5 g yeast extract, and 0.5 g NaCl were added to 950 mL 
sterile water and shaken until dissolved. To this solution, 10 mL of 250 mM KCl was 
added and the pH adjusted to 7.0. After autoclaving for 20 min, the medium was placed 
in a 55°C water bath to cool for about 30 min. Gentamicin (10 μg/mL) was added to the 
medium to prevent contamination, as suggested by published protocol for transformation 
of B. cenocepacia J2315 [116]. Right before the medium was used, 10 mL of sterile 1 M 
MgSO4 and 5 mL 2 M MgCl2 were added. SOC broth was made by adding 20 mL of a 1 
M glucose solution to 1 L SOB.  
 
B. cenocepacia Electrocompetent Cells  
 To create electrocompetent cells for transformations, an overnight culture of B. 
cenocepacia J2315 was grown in 5 mL SOB medium. The next day, the culture was 
diluted into an Erlenmeyer flask containing 50 mL SOB to make a final O.D.600 of 0.01. 
The flask was incubated with aeration at 37C for 2-3 generations, until the O.D.600 was 
between 0.04-0.08 based on the published protocol [116]. This equates to about 4-6 h of 
incubation. Next, the flask was chilled on ice for 5 min to stop bacterial growth, and the 
culture was aliquoted and centrifuged at 5000 x g for 8 min at 4°C (Kendro Lab Products, 
Sorvall Legend RT Centrifuge). The supernatant was removed, and the pellet was washed 
and resuspended in 20 mL ice-cold sterile 0.5 M sucrose, followed by two additional 
rounds of centrifugation, washing, and resuspension.  The final pellet was resuspended in 
0.5 mL 0.5 M sucrose. An LB and glycerol solution was added to make the final 
concentration 10% glycerol. The sample was divided into 500 μL aliquots and stored at   
-80°C until electroporation.  
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Transformation of B. cenocepacia J2315 
 Following the QIAprep Spin Miniprep Kit (Qiagen, #27106) protocol, plasmids 
encoding fluorescent proteins were purified from the E. coli DH5α strains provided by 
Dr. Annette Vergunst (University of Montpelier, France). These are listed in Table 2. The 
purity and DNA concentration for each purified plasmid was determined using a 
Nanodrop 2000 (Thermo Fisher Scientific). Plasmids were stored at -20C until use.  
 The plasmids, thawed electrocompetent B. cenocepacia cells, and electroporation 
cuvettes (VWR, #89047-206) were kept on ice. To 15 μL water, 0.1 g of each plasmid 
was added, followed by the addition of 55 μL of electrocompetent B. cenocepacia. The 
negative control consisted of electrocompetent cells without the addition of plasmid. 
After transferring this volume to a 2 mm electroporation cuvette, cells were 
electroporated at 2.5 kV (Bio-Rad Micropulser). Samples were removed from the cuvette 
by adding 950 μL SOC medium, and after gentle mixing, the volume was transferred to a 
microfuge tube. Samples were incubated at 37C, without aeration, for 4-5 h and plated 
on LB plates supplemented with 100 μg/mL chloramphenicol. Plates were incubated for 
three days. Single colonies were plated in patches on selective plates, and the resulting 
growth was observed under a confocal microscope to confirm fluorescence. Colonies that 
showed the proper fluorescence profile were stored in 20% glycerol at -80°C under the 
strain list designations shown in Table 1. 
 
Confocal Laser Scanning Microscopy Preparation and Analysis 
 To capture images of both single and co-culture biofilms, the fluorescent strains S. 
aureus AH1710 and B. cenocepacia J2315-62 were utilized. Each strain was individually 
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inoculated in test tubes containing 5 mL LB supplemented with 10 g/ml or 100 g/ml   
chloramphenicol, respectively.  Cultures were incubated at 37C overnight then diluted 
1:100 in TSB supplemented with 10 μg/mL chloramphenicol. Glass bottom FluoroDishes 
(World Precision Instruments, FD35-100) were used to grow the biofilms. Three sets of 
triplicate dishes were made for each monoculture and co-culture conditions. Dishes 
contained 3 mL of S. aureus AH1710, 3 mL of B. cenocepacia J2315-62, or 3 mL of a 
1:1 by volume mixture of the two. Confocal laser scanning microscopy (CLSM) analysis 
occurred at 1 day, 3 days, and 7 days post-inoculation of each condition. At each time 
point, the biofilm supernatant was discarded prior to microscopy. Both 2D and 3D 
imaging was captured using NIS-Element software with both the 40x and 60x lenses of a 
Nikon Eclipse Ti microscope. The GFP (487 nm) and TxRed (561 nm) lasers were used 
for excitation wavelengths. The power and gain of each image was optimized to show 
maximum fluorescence without saturation of the image.  
 
Statistical analyses 
All biofilm assays and viable cell count assays were graphed and analyzed using 
GraphPad Prism v. 5.1.0.  Statistical significance was calculated using either two-way 
ANOVA analysis, one-way ANOVA analysis in conjunction with Tukey’s multiple 
comparison test, or an unpaired T test, as indicated in each figure legend. Only p-values 





Choosing Material for Optimized Biofilm Formation 
 In order to test for the plate material that optimizes biofilm formation, 
representative strains of five common CF pathogens were chosen to form monoculture 
biofilms in 96 well plates made of two different materials. Twenty-four hour monoculture 
biofilms of S. aureus NRS77, B. cenocepacia J2315, A. xylosoxidans AU19284, P. 
aeruginosa C3719, and S. maltophilia K279a were grown in both round-bottom 96-well 
PVC plates and flat-bottom 96-well polystyrene plates. Biofilm was quantitated using the 
retention of crystal violet as described in the Materials and Methods. Results are shown 




Figure 1. Biofilm formation in polystyrene and PVC 96-well plates. The optical density of 
biofilm growth was obtained for one-day-old monocultures of A. xylosoxidans AU19284 (red), P. 
aeruginosa C3719 (orange), S. maltophilia K279a (green), S. aureus NRS77 (blue), and B. 
cenocepacia J2315 (purple) grown in both PVC and polystyrene 96-well plates. Two-way 
ANOVA analysis showed an overall significant effect of the interaction between strain type and 
plate material (p < 0.0001). Unpaired t-tests were used to calculate significance between strains 
grown on each plate material (*p < 0.05, ****p < 0.0001).  
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Unpaired t-tests of each strain showed that for all strains except S. maltophilia 
K279a, biofilm formation was significantly greater in 96-well PVC plates compared to 
polystyrene 96-well plates (Fig. 1).  S. maltophilia K279a grew optimally in the 
polystyrene 96-well plate but was still able to form biofilm that was comparable to the 
biofilm formation of the other four isolates in the 96-well PVC plate. Due to these 
observations, the 96-well PVC plate was chosen to use in all future biofilm formation 
assays.  
   
Co-culture Biofilms of Five CF Pathogens in Pairwise Combinations 
 After establishing that round-bottom, 96-well PVC plates were conducive for 
biofilm formation for a majority of the strains (Fig. 1), the same five isolates were tested 
for compatibility of biofilm formation in co-culture conditions. All pairwise 
combinations of B. cenocepacia J2315, S. aureus NRS77, A. xylosoxidans AU19284, P. 
aeruginosa C3719, and S. maltophilia K279a were inoculated in triplicate wells of a 96-
well PVC plate and incubated for 1 or 3 days. Biofilm quantitation was completed using 
sonication and drip dilutions, and viable cell counts for each strain in co-culture were 
compared to each strain in monoculture.  
Supplementary Figure 1 shows the data and summarizes the results for 
monoculture and co-culture biofilm formation of A. xylosoxidans AU19284, P. 
aeruginosa C3719, and S. maltophilia K279a.  The data for B. cenocepacia J2315 and S. 
aureus NRS77 (Fig. 2) suggested that the presence of S. aureus NRS77 has no effect on 
B. cenocepacia J2315 biofilm formation, but the presence of B. cenocepacia J2315 
results in a reduction in viable cells below the limit of detection for S. aureus NRS77 
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biofilm by day 3. These results suggested that the presence of B. cenocepacia J2315 may 
inhibit S. aureus NRS77 biofilm formation over time. 
 
 
Figure 2. Biofilm formation of B. cenocepacia J2315 and S. aureus NRS77 in co-culture 
conditions. Viable cell counts of (A) S. aureus NRS77 biofilms and (B) B. cenocepacia J2315 
biofilms when grown in co-culture with A. xylosoxidans (red), P. aeruginosa C3719 (orange), S. 
maltophilia K279a (green), S. aureus NRS77 (blue), or B. cenocepacia J2315 (purple). Presence 
of an “X” indicates exclusion of data due to contamination of samples. Absence of a bar indicates 
the viable counts are below the limit of detection (gray line), which was 105 for this experiment. 
One-way ANOVA analysis showed an overall significant difference among means (p < 0.05) in 
CFU/mL within both S. aureus NRS77 and B. cenocepacia J2315 data. Tukey’s multiple 
comparison test was used to compare co-culture and monoculture conditions (*p < 0.05). 
 
Effect of B. cenocepacia J2315 on S. aureus Strains 
 Next, the ability of B. cenocepacia J2315 to inhibit biofilm formation in other S. 
aureus strains was tested. It was hypothesized that inhibition of S. aureus biofilm by B. 
cenocepacia J2315 would not be limited to the NRS77 strain. Mixes of B. cenocepacia 
J2315 and four S. aureus strains – NRS77, NRS72, AH2183, and AH3865 – were made 
and inoculated in a 96-well PVC plate and allowed to incubate for 1, 3, or 7 days before 
the co-culture biofilms were quantitated by sonication and drip dilutions. The viable cell 
count was then compared to viable counts from monoculture biofilms.  
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There was no statistical significance in biofilm formation of B. cenocepacia J2315 
between S. aureus strains or over time (Fig. 3), while all tested S. aureus strains were 
inhibited over time by the presence of B. cenocepacia J2315 (Fig. 4). Viable S. aureus 
NRS77 biofilm was below the limit of detection (103 CFU/mL) in the presence of B. 
cenocepacia J2315 (Fig. 4A). Biofilms of S. aureus NRS72 were present after growing 
for 1 day with B. cenocepacia J2315, but growth was significantly inhibited in 
comparison to the monoculture biofilm, and by day 3, viable S. aureus NRS72 biofilm 
was reduced beyond the limit of detection in co-culture with B. cenocepacia J2315 (Fig. 
4B).  
 
Figure 3. Effect of S. aureus strains on B. cenocepacia J2315 survival in co-culture biofilms. 
B. cenocepacia J2315 was mixed with S. aureus strains NRS77, NRS72, AH3862, or AH2183 for 
1, 3, or 7 days. Biofilm formation was quantitated using sonication and drip dilutions, and biofilm 
viable cell counts were compared to monoculture biofilm growth of B. cenocepacia J2315. One-
way ANOVA with Tukey’s multiple comparison test showed no significant difference over time 
or between co-culture conditions. 
 
S. aureus AH3865 was able to form biofilm as effectively in the presence of B. 
cenocepacia J2315 as in monoculture during day 1, but was significantly inhibited by day 
3 (Fig. 4C). S. aureus AH2183 biofilm formation appeared to be inhibited in the presence 
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of B. cenocepacia J2315 after 1 day, but this effect was not statistically significant (Fig. 
4D). On day 3, however, the decrease in S. aureus AH2183 co-culture biofilm was 
statistically significant in comparison to monoculture. All strains of S. aureus had no 
detectable biofilm on day 7 in the presence of B. cenocepacia J2315. This data suggests 




Figure 4. Effect of B. cenocepacia J2315 on multiple S. aureus strains during biofilm 
formation over time. S. aureus strains NRS77 (A), NRS72 (B), AH3865 (C), and AH2183 (D) 
were grown in monoculture and in co-culture with B. cenocepacia J2315 for 1, 3, or 7 days. 
Biofilm formation was quantitated using sonication and drip dilutions. Bars representing biofilm 
formation of S. aureus strains grown alone (blue) or grown in co-culture with B. cenocepacia 
J2315 (purple striped) are shown.  Limit of detection is indicated by the gray line. Unpaired t-test 
measured significant differences as indicated by brackets and asterisks (*p < 0.05, **p < 0.01, 
****p < 0.0001).   
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Standardizing the Viable Cell Count of Isolates with O.D.600 
 In the previous experiments, an equal volume of each overnight culture was used 
when inoculating 96-well plates for co-culture biofilm formation. However, because S. 
aureus is a coccus and B. cenocepacia is a bacillus, the size difference between species 
may result in a different concentration of cells per unit volume of medium. Additionally, 
the viable cell count of overnight cultures within one strain may not be consistent 
between replicates. We sought to eliminate the difference in cell number between B. 




Figure 5. Viable cell count of isolates with O.D.600 of 0.8. Overnight cultures were diluted in 
fresh LB and grown to O.D.600 of 0.8, serial diluted, and plated. Viable cell counts were collected 
for B. cenocepacia J2315, and the indicated S. aureus. One-way ANOVA analysis showed no 
significant differences between strains. 
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Performing drip dilutions on cultures with an O.D.600 of 0.8 standardizes the 
viable cell count of each strain. This process was completed for B. cenocepacia J2315 
and for S. aureus strains NRS77, AH3865, AH2183, AH1710, and AH2547. Results  
show that all S. aureus strains had an average concentration of approximately 108 
CFU/mL at this O.D.600 reading, while B. cenocepacia J2315 had an average 
concentration around 109 CFU/mL (Fig. 5). Therefore, when creating 50/50 mixes of B. 
cenocepacia J2315 and any of the aforementioned S. aureus strains grown to O.D.600 of 
0.08, B. cenocepacia J2315 may have 10-fold the number of cells compared to S. aureus. 
This led to a fundamental change in our experimental design. In the following 
experiments, after strains reached an O.D.600 of 0.8, B. cenocepacia J2315 was diluted 
10-fold in comparison to S. aureus NRS77 to account for differences in cell size.  
 
Effect of B. cenocepacia J2315 on Pre-Established S. aureus NRS77 Biofilms 
 The results from the above experiments show that the J2315 strain of B. 
cenocepacia is able to prevent S. aureus from forming and maintaining the biofilm 
lifestyle. We sought to determine if B. cenocepacia J2315 is also able to destroy mature 
S. aureus NRS77 biofilms. We hypothesized that mature S. aureus biofilms would be 
able to survive inoculation of B. cenocepacia J2315, but biofilm viable cell counts would 
show a progressive decrease over time, while B. cenocepacia J2315 biofilms would be 
unaffected.  
 S. aureus biofilms were formed for 3 days before the addition of either more S. 
aureus NRS77, a 50/50 mixture of S. aureus NRS77 and B. cenocepacia J2315, or B. 
cenocepacia J2315. After 1 day, there was no significant difference between S. aureus 
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biofilms of any treatment (Fig. 6). On day 3, there was a significant decrease in S. aureus 
NRS77 biofilm in both the treatment with B. cenocepacia J2315 / S. aureus NRS77 
mixture and the treatment with B. cenocepacia J2315. Only the treatment with B. 
cenocepacia J2315 showed a statistically significant decrease in S. aureus NRS77 biofilm 
formation on day 7. In addition, compared to monoculture conditions, there was no 
statistically significant difference in B. cenocepacia J2315 biofilm formation in the 




Figure 6. Inhibition of mature S. aureus NRS77 biofilms by B. cenocepacia J2315. Mature, 3-
day old S. aureus NRS77 biofilms were inoculated with S. aureus NRS77 (blue), a 50:50 mixture 
of S. aureus NRS77 and B. cenocepacia J2315 cultures (purple striped), or B. cenocepacia J2315 
(blue bar, purple outline) and grown for 1, 3, and 7 days. Biofilms were quantitated for each 
condition using sonication and drip dilutions. Limit of detection is indicated by a gray line. One-
way ANOVA with Tukey’s multiple comparison tests analyzed significant differences of biofilm 
formation between treatments (*p < 0.05, **p < 0.01 ***p < 0.001).   
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Together, these data continue to support the hypothesis that B. cenocepacia J2315 
is diminishing the ability of S. aureus NRS77 to form or maintain a biofilm state. Not 
only does B. cenocepacia J2315 prevent biofilm formation of S. aureus NRS77 upon 
simultaneous inoculation, but it also results in the reduction of S. aureus NRS77 biofilm 
that has already been established. It is not clear if this inhibition is due to the presence of 




Exploring the Mechanism of S. aureus Biofilm Inhibition 
 This experiment was designed to determine if inhibition of S. aureus biofilm by 
B. cenocepacia was through a secreted or shed product, and to determine if live B. 
cenocepacia cells are necessary for S. aureus biofilm destruction. Five B. cenocepacia 
J2315 treatments for S. aureus biofilms were chosen to answer these mechanistic 
questions and are depicted in Table 2. B. cenocepacia J2315 seems to specifically inhibit 
biofilm formation in S. aureus and does not appear to reduce biofilm of other tested 
species (Supplementary Fig. 1). Due to these observations, it was hypothesized that B. 
cenocepacia J2315 needed to recognize the presence of S. aureus NRS77 to mediate 
biofilm reduction, and would, therefore, require the presence of live B cenocepacia J2315 
cells.   
For clarification, the results from this experiment have been separated into four 
sections: the effect of sonicated B. cenocepacia J2315 cells, B. cenocepacia J2315 
biofilm supernatant, B. cenocepacia J2315 overnight supernatant, and B. cenocepacia 
J2315 pelleted planktonic cells on S. aureus NRS77 biofilms.  The effects of all B. 
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cenocepacia J2315 fractions on S. aureus NRS77 biofilms were compared to 
monoculture S. aureus NRS77 biofilm formation. In addition, results could be compared 
to the inhibition of S. aureus NRS77 biofilms treated with whole B. cenocepacia J2315 
culture. This was the same condition tested in previous experiments and therefore acted 
as a positive control for S. aureus NRS77 biofilm inhibition. 
Table 2. Experimental design for exploring possible mechanisms of B. cenocepacia 
J2315-mediated destruction of S. aureus NRS77 biofilm 
 
The effect of sonicated B. cenocepacia J2315 cells on S. aureus NRS77 biofilms 
B. cenocepacia J2315 was subjected to sonication in order to lyse cells.  
Following the sonication treatment, serial and drip dilutions of lysed cells suggested no 
detectable levels of viable B. cenocepacia cells remained (data not shown). This 
sonicated mixture was mixed with TSB 1:1 (v/v) and added to one-day-old S. aureus 
NRS77 biofilm. Biofilms were incubated for 3 days. The resulting data shows that there 
Treatment Source Purpose or question addressed 
Whole B. cenocepacia 
J2315 
Overnight culture 






(1) Is live B. cenocepacia J2315 necessary 
for S. aureus biofilm reduction? 
B. cenocepacia J2315 
biofilm supernatant 
Filter-sterilized 
supernatant of a 3-day-old 
monoculture biofilm 
(1) Do biofilm secretions result in S. 
aureus  biofilm reduction? 
 
(2) Is cell-to-cell contact necessary for S. 
aureus  biofilm reduction? 
B. cenocepacia J2315 
overnight supernatant 
Filter-sterilized 
supernatant of an 
overnight culture 
(1) Do planktonic secretions result in S. 
aureus biofilm reduction? 
 
(2) Is cell-to-cell contact necessary for S. 
aureus biofilm reduction? 
Pelleted/resuspended 
 B. cenocepacia 
Overnight culture, pelleted 
and resuspended in fresh 
medium 
(1) Are cells alone sufficient to induce S. 
aureus biofilm reduction? 
 
(2) Is cell-to-cell contact necessary for S. 
aureus biofilm reduction? 
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was no significant difference in the viable cell count of the S. aureus NRS77 biofilm and 
the S. aureus biofilm exposed to sonicated B. cenocepacia J2315 (Fig. 7). In comparison, 
the significant inhibition of the S. aureus NRS77 biofilm due to the B. cenocepacia J2315 
control on day three suggests that the process that leads to S. aureus biofilm antagonism 
requires live B. cenocepacia J2315.  
 
Figure 7. Effect of B. cenocepacia J2315 components on S. aureus NRS77 biofilm. One-day-old S. 
aureus NRS77 biofilm was inoculated with either TSB or one of five experimental treatments. S. 
aureus NRS77 biofilm was quantitated after three days using sonication and drip dilutions. One-way 
ANOVA analysis showed a significant effect of treatment (p < 0.0001), and Tukey’s multiple 
comparison test analyzed for significant difference of treatments in comparison to the treatment with 
whole B. cenocepacia J2315 (Red box; *p < 0.05, ***p < 0.001, ****p < 0.0001) and the S. aureus 
monoculture condition (Green box; p < 0.05,p < 0.0001). Statistical difference of S. aureus 
NRS77 biofilm formation between B. cenocepacia J2315 overnight and biofilm supernatant 
treatments is also shown (p < 0.001). 
 
The effect of B. cenocepacia J2315 biofilm supernatant on S. aureus NRS77 biofilms 
 B. cenocepacia J2315 biofilm was grown for three days, and the supernatant was 
collected and filter-sterilized before being mixed with TSB for addition to a one-day-old 
S. aureus NRS77 biofilm. After incubation for 3 days, the S. aureus NRS77 biofilm 
viable cell count was measured following sonication and drip dilutions. Analysis of the 
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resulting data shows exposure to the biofilm supernatant caused a statistically significant 
decrease in S. aureus NRS77 biofilms compared to the S. aureus NRS77 monoculture 
biofilms. There was no statistically significant difference in S. aureus NRS77 biofilm 
inhibition when comparing the exposure to whole B. cenocepacia J2315 to the exposure 
to B. cenocepacia J2315 biofilm supernatant.  
Both the presence of B. cenocepacia J2315 cells and the exposure to B. 
cenocepacia J2315 biofilm supernatant results in a reduction of S. aureus NRS77 biofilm. 
This suggests that B. cenocepacia J2315 is secreting or shedding a substance during 
biofilm formation that is a potential inhibitor of S. aureus NRS77 biofilms. Additionally, 
B. cenocepacia J2315 does not require the presence of S. aureus NRS77 for production of 
the inhibiting substance. 
 
The effect of B. cenocepacia J2315 overnight supernatant on S. aureus NRS77 biofilms 
 The overnight culture of B. cenocepacia J2315 was centrifuged and the 
supernatant was collected, filter-sterilized, and stored in a 1:1 mixture of a glycerol 
solution for storage until use. On the day of inoculation of one-day-old S. aureus NRS77 
biofilm, the supernatant glycerol solution was mixed 1:1 (v/v) with TSB and added to S. 
aureus NRS77 biofilms. Quantitative analysis through sonication and drip dilutions was 
completed for S. aureus NRS77 biofilms after three days of incubation.  
B. cenocepacia J2315 overnight supernatant decreased S. aureus NRS77 biofilm 
to a mild but significantly lower level compared to treatment with whole B. cenocepacia 
J2315 (Fig. 7). These results suggest that B. cenocepacia J2315 may be able to secrete or 
shed a product during growth of overnight culture that results in a slight reduction of S. 
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aureus NRS77 biofilms. However, because the effect of the overnight supernatant 
treatment did not result in the same level of inhibition as whole cultures, this suggests 
that either an inhibitory molecule is not optimally expressed during overnight growth or 
that there is an additive effect of B. cenocepacia J2315 cells and supernatant on S. aureus 
biofilm inhibition.  
 
The effect of pelleted planktonic cells on S. aureus NRS77 biofilms 
 An overnight culture of B. cenocepacia J2315 was centrifuged, and the 
supernatant was removed. The resulting pellet was resuspended and diluted in fresh TSB 
then added to one-day-old S. aureus NRS77 biofilm and incubated for one or three days. 
Biofilm was quantitated through sonication and drip dilutions. Statistical analysis showed 
that after three days the viable cell count of S. aureus NRS77 biofilms was statistically 
lower than the monoculture S. aureus NRS77 biofilms but not statistically different than 
the S. aureus NRS77 biofilms exposed to whole B. cenocepacia J2315 (Fig. 7). This 
result indicates that B. cenocepacia J2315 cells, both with and without supernatant from 
overnight growth, are capable of reducing S. aureus NRS77 biofilm to the same extent. 
Altogether, the data presented above suggest that our original hypothesis 
regarding a potential mechanism of S. aureus biofilm reduction was likely incorrect. B. 
cenocepacia J2315 does not require the presence of  S. aureus NRS77 in order to produce 
an inhibitory effect on S. aureus NRS77 biofilm viability. It appears as if there is an 
antagonistic substance in the supernatant of B. cenocepacia J2315 – both from cells in a 
planktonic and biofilm lifestyle  – that interacts with S. aureus NRS77 biofilm in a way 
that leads to a reduction in the viable cell count of cells in the biofilm.  
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Transformation of B. cenocepacia J2315 
 To better understand the interactions between S. aureus strains and B. 
cenocepacia J2315 in biofilms, strains encoding fluorescent proteins were obtained.  S. 
aureus strains bearing GFP- and dsRedExpress-encoding plasmids (Table 1) were 
obtained from Dr. Alexander Horswill at the University of Iowa. To generate fluorescent 
B. cenocepacia J2315, a protocol established by Dubarry et al. [116] was followed, and 
transformants of B. cenocepacia J2315 expressing GFP (J2315-301), mCherry (not 
named) and dsRedExpress (J2315-62) were created. The mCherry transformants showed 
weak fluorescence and were quick to photobleach, while both the GFP strain and 
dsRedExpress strains showed strong fluorescence that did not fade quickly. The latter 
two strains were used in conjunction with the provided S. aureus strains to observe co-
culture biofilms with confocal laser scanning microscopy, which allows 3-dimensional 
biofilm structures to be observed.  
 
Phenotypes of Co-culture Biofilms 
 To observe the phenotypic and spatial interaction between these organisms, 
strains B. cenocepacia J2315-62 (red fluorescence) and S. aureus AH1710 (green 
fluorescence) were grown in triplicate in both co-culture and monoculture conditions for 
1, 3, or 7 days in glass-bottomed petri dishes. In addition, another set of dishes were 
inoculated with S. aureus AH1710 monoculture and incubated for 3 days.  The S. aureus 
supernatant was then replaced with filter-sterilized supernatant of 3-day-old B. 
cenocepacia J2315 biofilm, and the dishes were incubated with the remaining plates. It 
was hypothesized that the destruction of S. aureus biofilm formed in co-culture with B. 
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cenocepacia J2315-62 would be observable over time. Additionally, because B. 
cenocepacia J2315 reduces biofilm in several S. aureus strains, we also predicted that S. 
aureus AH1710 biofilm exposed to B. cenocepacia J2315 biofilm supernatant would be 
reduced.  
First, S. aureus AH1710 and B. cenocepacia J2315-62 form morphologically 
different biofilms in monoculture compared to co-culture. Single cultures of S. aureus 
AH1710 laid down a biofilm in a flat mat, with little to no clustering morphology (Figs. 
8A and B), while S. aureus AH1710 cells in co-cultures with B. cenocepacia can 
regularly be seen in both flat mats on the surface of the dish and in mixed species 
mushroom structures with B. cenocepacia J2315-62 (Figs. 8E and F). The biofilm formed 
by B. cenocepacia J2315-62 in monoculture is highly clustered and porous, resembling 
honeycomb (Figs. 8C and D). These structures are less apparent when grown in co-
culture with S. aureus AH1710, where as B. cenocepacia biofilm phenotype appears to 
switch from a porous morphology to a mushroom-like structure that surround 
clusters of S. aureus (Figs. 8E and F).  
While co-culture experiments using 96-well PVC plates showed an absence of 
biofilm of four S. aureus strains by day 7 when inoculated simultaneously with B. 
cenocepacia J2315 (Figs. 1 and 2), S. aureus AH1710 is still present in the co-culture 
biofilm after the same amount of time in co-culture, albeit to a reduced degree (Fig. 9B). 
However, S. aureus AH1710 biofilm exposed to 3-day-old sterile supernatant of B. 
cenocepacia J2315 appears markedly decreased in comparison to the co-culture 
condition. This difference in S. aureus biofilm reduction can be seen in Figure 9B and C. 
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Figure 8. CLSM imaging of single and co-culture biofilms of B. cenocepacia J2315-62 and S. 
aureus AH1710 over time. Triplicate glass bottom dishes were inoculated with either single 
cultures (A-D) or co-cultures (E and F) of B. cenocepacia J2315-62 and S. aureus AH1710 and 
grown for 3 (A, C, and E) and 7 days (B,D, and F). Images were captured using NIS-Elements 
software, and settings were optimized for each image.  
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Based on these observations, it seems as if the presence of B. cenocepacia cells 
may be slowing the progression of S. aureus biofilm destruction that results from B. 
cenocepacia J2315 secretions when grown in the glass bottom dishes. Alternatively, the 
timing of biofilm inhibition may be variable between cultures grown in PVC 96-well                    
plates and cultures grown in glass-bottom dishes. A longer time period may be required 
to see the same levels of inhibition in the glass bottom dishes that is observed in the 96-
well PVC plate. 
 
Figure 9. Effect of B. cenocepacia J2315 biofilm supernatant on S. aureus AH1710 biofilm. 
(A) Monoculture, 7-day-old S. aureus AH1710 biofilm. (B) A 7-day-old co-culture biofilm image 
with the red channel (B. cenocepacia J2315-62) removed, and only the green channel (S. aureus 
AH1710) displayed. (C) Three-day-old S. aureus AH1710 biofilm inoculated with 25% B. 
cenocepacia J2315 biofilm supernatant in TSB, and incubated for an additional four days. 
 
Although it was shown that both B. cenocepacia J2315 cells and biofilm 
supernatant reduce S. aureus biofilm to the same extent (Fig. 7), it is clear that some sort 
of alternate interaction is occurring under the conditions of this experiment. The presence 
of B. cenocepacia cells still reduces S. aureus biofilm, but appears to slow that reduction 
compared to the presence of biofilm supernatant alone. This effect could be due to the 
difference in the experimental design between the 96-well plate experiments and the 
CLSM experiments. The glass-bottom dishes used for biofilm attachment in this 
experiment held a larger volume of inoculated medium compared to the 96-well PVC 
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plates used in other experiments. Difference in material or total medium volume may 
influence the time it takes for reduction in S. aureus biofilm to occur.  
Another possibility is that the substance in the biofilm secretion that results in S. 
aureus biofilm destruction is regulated and taken back up by B. cenocepacia. The 
presence of B. cenocepacia J2315-62 would decrease the concentration of the biofilm-
destroying-substance, thereby slowing S. aureus biofilm degradation in a dose-dependent 
manner. This is speculative, and further experimentation needs to be done to identify the 




 Most of the published literature chronicling CF pathogenesis focus on single 
culture biofilms of pathogens either in vitro or in vivo; however, co-culture biofilms are 
common in nature and in human hosts during the course of disease and thus warrant 
further study. Multiple strains and species are commonly cultured from CF lungs [103], 
and the unique interactions that may occur in the biofilms of these isolates could provide 
key insight into the varying pathogenicity of the disease. The analysis of co-culture 
biofilm formation of B. cenocepacia and S. aureus explored in this study has shown a 
novel interaction with important implications. 
 In this study, we found that B. cenocepacia J2315 secretions result in the 
degradation of S. aureus biofilm and prevent S. aureus biofilm formation in several 
strains. Even when given the opportunity to form mature biofilms, B. cenocepacia J2315 
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degrades S. aureus biofilm over time. In contrast, the presence of S. aureus NRS77 does 
not seem to alter biofilm formation or maintenance in B. cenocepacia J2315.  
The exact mechanism of this interaction remains unclear, although there exist 
several explanative possibilities. First, B. cenocepacia secretion may be altering the pH 
of the medium. However, destruction of S. aureus biofilm is not likely occurring due to 
decreasing the pH. The CF lung, which S. aureus frequently infects, is acidic in 
comparison to a healthy lung due to the improper transport of bicarbonate ions [117]. 
Additionally, low pH can be an environmental signal to initiate biofilm formation in 
staphylococcal species [118]. Its ability to survive in low pH conditions suggests a 
different mechanism is causing degradation of S. aureus biofilm. Further, our data 
suggests this inhibitory effect may be specific to S. aureus, as similar inhibition was not 
observed for P. aeruginosa or S. maltophilia (Supplementary Fig. 1). A generalized 
mechanism such as decreased pH would theoretically affect biofilm formation in other 
species as well. Absence of this effect insinuates that the substance secreted by B. 
cenocepacia J2315 specifically targets S. aureus or a component of the S. aureus biofilm.  
 Another possible mechanism leading to S. aureus biofilm destruction is through 
the destruction of the EPS holding the biofilm together, such as through secretions of 
polysaccharide hydrolases, DNases, and/or proteases.  This destruction would result in 
release of cells from the bacterial matrix and back to planktonic growth. This explanation 
is easily testable by removing the liquid from a co-culture biofilm, quantitating 
planktonic bacteria, and comparing the viable cell count to the CFU/mL of the planktonic 
culture of S. aureus monoculture biofilm. The presence of a greater viable cell count of 
planktonic S. aureus in co-culture with B. cenocepacia compared to S. aureus in single 
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culture would suggest the biofilm matrix is being dissolved and releasing the cells back 
into the medium.  
Destruction of S. aureus biofilm in such a manner would not be a novel finding. A 
serine protease secreted by Staphylococcus epidermidis termed Esp has been shown to 
degrade both molecules in the matrix of S. aureus biofilm and molecules essential for 
biofilm formation and colonization, such as fibronectin binding proteins [119]. Exposure 
to Esp results in degradation of established S. aureus biofilm over time in a similar 
manner as exposure to B. cenocepacia and its biofilm supernatant.  
 Other potential mechanisms to explain the antagonism of secreted compounds to 
S. aureus biofilm could be the production of reactive oxygen species (ROS) in the 
medium or the production of biofilm-inhibiting lipids. ROS secretion by B. cenocepacia 
is less likely, as some Bcc members are killed by certain antibiotics through a resulting 
increase in ROS production [120].  
Production of biofilm-inhibiting lipids, on the other hand, is a possible 
mechanism of S. aureus biofilm reduction. Rhamnolipids produced by P. aeruginosa 
have anti-staphylococcal activity [121] and act to decrease biofilm formation in order to 
maintain water channels [122]. B. cenocepacia J2315 has been shown to possess the 
operon required for rhamnolipid production [123], although the production of 
rhamnolipids has not yet been reported in this species. However, the porous biofilm 
phenotype shown in our study suggests the importance of water channels in B. 
cenocepacia biofilm maturation and maintenance, hinting at a possible role or expression 
of the rhamnolipid regulating operon. As a typically aerobic species, access to oxygen is 
critical for B. cenocepacia survival. Maintenance of biofilm water channels for access to 
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fresh nutrients and oxygen implicate the potential importance of rhamnolipids in B. 
cenocepacia virulence, and is therefore a potential mechanism of S. aureus biofilm 
inhibition.  
In addition to rhamnolipids, B. cenocepacia J2315 produces a lipopeptide capable 
of lysing human cells and inhibiting growth of both S. aureus and P. aeruginosa strains 
[124]. However, this lipopeptide was only produced at effective concentrations with 
vigorous shaking for three days. Our data suggest that the substance secreted by B. 
cenocepacia J2315 that inhibits S. aureus biofilm is produced under static conditions for 
the same amount of time. It is therefore probable that the inhibition of S. aureus observed 
in our data is not occurring through actions of this lipopetide.  
Further research into the identity of the B. cenocepacia J2315 secreted substance 
could clarify the discrepancy seen in the significant reduction of S. aureus AH1710 
biofilm exposed to B. cenocepacia supernatant during CLSM imaging. Co-culture 
imaging showed that S. aureus AH1710 was still present in 7-day-old co-culture biofilm 
with B. cenocepacia J2315, while B. cenocepacia supernatant in the absence of viable B. 
cenocepacia cells resulted in intensified S. aureus AH1710 biofilm reduction.   
A possible mechanism explaining this S. aureus biofilm reduction is the secretion 
and re-uptake of a toxic or catabolic substance by B. cenocepacia. P. aeruginosa has 
been shown to produce siderophores that are toxic to S. aureus and lead to cell lysis as a 
way to scavenge iron [125]. Siderophores are secreted to collect iron from the 
environment and are then taken back up by the bacteria. A similar mechanism used by B. 
cenocepacia may explain the presence of S. aureus biofilm in co-culture with B. 
cenocepacia (Fig. 7E and 7F) in the CLSM experiment, whereas the presence of the B. 
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cenocepacia biofilm supernatant without B. cenocepacia cells resulted in S. aureus 
biofilm destruction (Fig. 9). If B. cenocepacia is secreting a molecule that destroys S. 
aureus biofilm but the molecule can be taken back up into the cell, then the presence of 
B. cenocepacia could be somewhat ameliorating to S. aureus biofilm degradation in such 
a situation. B. cepacia complex isolates have been shown to produce a variety of 
siderophores including ornibactin, pyochelin, salicylic acid, and cepabactin [126-129]. 
 There are many hypotheses to be explored and tested as a result of the data 
presented in this thesis. Though the exact mechanism underlying the B. cenocepacia 
mediated destruction of S. aureus biofilm remains to be elucidated, the degradation of S. 
aureus biofilm by a potentially novel substance is an exciting finding. The increasing 
prevalence of antibiotic resistance in both MSSA and MRSA necessitates the discovery 
of both new antibacterials and targets for therapeutics.  
 There are antibacterials on the market that can effectively treat S. aureus infection 
in CF and other individuals [130], but antibiotic resistance by bacteria protected in 
biofilms prevents treatment of the underlying infection. Should further experimentation 
reveal that the substance secreted or shed by B. cenocepacia results in dissolution of S. 
aureus biofilm matrix, it could implicate a potential therapeutic solution to elimination of 
S. aureus biofilms. 
 Future directions for this research include the identification of the substance of 
interest being secreted by B. cenocepacia J2315, use of tissue cultures as a surface for co-
culture biofilm formation, analysis and comparison of gene expression between B. 
cenocepacia planktonic and biofilm lifestyles, as well as continuous capture of CLSM 
images to create and observe a time lapse of co-culture biofilm formation and S. aureus 
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biofilm degradation. Results from these proposed experiments, used in conjunction with 
the findings of this paper, could reveal a novel antimicrobial agent or a new target for S. 




 I would like to give my thanks and gratitude to Dr. Deborah Yoder-Himes for the 
never-ending support, guidance, and contagious enthusiasm she has given throughout the 
completion of this project. I want to thank Dr. Patricia Soucy and Betty Nunn for use of 
the confocal microscope and Dr. Annette Vergunst and Dr. Alexander Horswill for 
providing the fluorescent strains utilized in this thesis. I would also like to thank my 
fellow lab members, Akhila Ankem, Lauren Barrett, Kryshawna Beard, TJ Brandt, Brad 
Clark, Tom Hundley, and Steve Tran, for the problems they have helped me solve, the 
encouragement they have given, and for providing a lab environment where learning and 
camaraderie go hand-in-hand.  Funding for this project was provided by the University of 










1. Palomaki, G. E. F., S. C.; Haddow, J. E. (2004). "Clinical sensitivity of prenatal 
screening for cystic fibrosis via CFTR carrier testing in a United States 
panethnic population." Genet Med. 6(5): 405-414. 
 
2. Gustafsson, J. K. E., A;  Ambort, D; Johansson, M. E.V.; Nilsson, H. E.; 
Thorell, K.; Hebert, H.;  Sjovall, H.; Hansson, G. C. (2012). "Bicarbonate and 
functional CFTR channel are required for proper secretion and link cystic 
fibrosis with its mucus phenotype." The Journal of Experimental Medicine 
209(7): 1263-1272. 
 
3. Claustres, M., Guittard, C., Bozon, D., Chevalier, F., Verlingue, C., Ferec, C., . . 
. Georges, M. D. (2000). Spectrum of CFTR mutations in cystic fibrosis and in 
congenital absence of the vas deferens in France. Hum Mutat, 16(2), 143-156.  
 
4. Zabner, J., Smith, J. J., Karp, P. H., Widdicombe, J. H., & Welsh, M. J. (1998). 
Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway 
epithelia in vitro. Mol Cell, 2(3), 397-403. 
 
5. Smith, J. J., Travis, S. M., Greenberg, E. P., & Welsh, M. J. (1996). Cystic 
fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface 
fluid. Cell, 85(2), 229-236.  
 
6. Abou Alaiwa, M. H. R., L. R.; Gansemer, N. D.; Sheets, K. A.; Horswill, A. R.; 
Stoltz, D. A.; Zabner, J.; Welsh, M. J. (2014). "pH modulates the activity and 
synergism of the airway surface liquid antimicrobials β-defensin-3 and LL-37." 
Proc Natl Acad Sci U S A 111(52): 18703-18708. 
 
7. Pezzulo, A. A.; Tang, X. X.; Hoegger, M. J.; Abou Alaiwa, M. H.; 
Ramachandran, S.; Moninger, T. O.; Karp, P. H.; Wohlford-Lenane, C. L.; 
Haagsman, H. P.; van Eijk, M.; Banfi, B.; Horswill, A. R.; Stoltz, D. A.; 
McCray, P. B., Jr.; Welsh, M. J; .Zabner, J. (2012). Reduced airway surface pH 
impairs bacterial killing in the porcine cystic fibrosis lung. Nature, 487(7405), 
109-113. doi:10.1038/nature11130 
 
8. Flynn, J. M., Niccum, D., Dunitz, J. M., & Hunter, R. C. (2016). Evidence and 
Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease. PLoS 
Pathog, 12(8), e1005846. doi:10.1371/journal.ppat.1005846 
 
9. Ashford, T. P., & Porter, K. R. (1962). Cytoplasmic components in hepatic cell 
lysosomes. J Cell Biol, 12, 198-202.  
 
10. Jessup, W., & Dean, R. T. (1983). Endocytosis and intracellular protein 
degradation in cystic fibrosis fibroblasts. Clin Chim Acta, 129(3), 333-339.  
 
 52 
11. Luciani, A., Villella, V. R., Esposito, S., Brunetti-Pierri, N., Medina, D. L., 
Settembre, C., . . . Maiuri, L. (2011). Cystic fibrosis: a disorder with defective 
autophagy. Autophagy, 7(1), 104-106.  
 
12. Mayer, M. L., Blohmke, C. J., Falsafi, R., Fjell, C. D., Madera, L., Turvey, S. 
E., & Hancock, R. E. (2013). Rescue of dysfunctional autophagy attenuates 
hyperinflammatory responses from cystic fibrosis cells. J Immunol, 190(3), 
1227-1238. doi:10.4049/jimmunol.1201404 
 
13. Bonfield, T. L., Panuska, J. R., Konstan, M. W., Hilliard, K. A., Hilliard, J. B., 
Ghnaim, H., & Berger, M. (1995). Inflammatory cytokines in cystic fibrosis 
lungs. Am J Respir Crit Care Med, 152(6 Pt 1), 2111-2118. 
doi:10.1164/ajrccm.152.6.8520783 
 
14. Kube, D., Sontich, U., Fletcher, D., & Davis, P. B. (2001). Proinflammatory 
cytokine responses to P. aeruginosa infection in human airway epithelial cell 
lines. Am J Physiol Lung Cell Mol Physiol, 280(3), L493-502.  
 
15. Tabary, O., Zahm, J. M., Hinnrasky, J., Couetil, J. P., Cornillet, P., Guenounou, 
M., . . . Jacquot, J. (1998). Selective up-regulation of chemokine IL-8 
expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J 
Pathol, 153(3), 921-930. doi:10.1016/S0002-9440(10)65633-7 
 
16. Clunes, M. T. a. B., R. C. (2007). Cystic Fibrosis: The Mechanisms of 
Pathogenesis of an Inherited Lung Disorder. Drug Discov Today Dis Mech, 
4(2), 63-72. doi:10.1016/j.ddmec.2007.09.001 
 
17. Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999). Bacterial biofilms: a 
common cause of persistent infections. Science, 284(5418), 1318-1322. 
  
18. Hoiby, N., Ciofu, O., & Bjarnsholt, T. (2010). Pseudomonas aeruginosa 
biofilms in cystic fibrosis. Future Microbiol, 5(11), 1663-1674. 
doi:10.2217/fmb.10.125 
 
19. Saukkonen, K., Sande, S., Cioffe, C., Wolpe, S., Sherry, B., Cerami, A., & 
Tuomanen, E. (1990). The role of cytokines in the generation of inflammation 
and tissue damage in experimental gram-positive meningitis. J Exp Med, 
171(2), 439-448.  
 
20. Soni, R., Dobbin, C. J., Milross, M. A., Young, I. H., & Bye, P. P. (2008). Gas 
exchange in stable patients with moderate-to-severe lung disease from cystic 
fibrosis. J Cyst Fibros, 7(4), 285-291.  
 
21. 2015 Annual Data Report, Cystic Fibrosis Foundation Patient Registry (2016). 
Cystic Fibrosis Foundtation. 
 
 53 
22. Thurlow, L. R.; Hanke, M. L., Fritz, T.; Angle, A., Aldrich, A.; Williams, S. H.; 
Engebretsen, I. L.;  Bayles, K. W.;  Horswill, A. R.; Kielian, T. (2011). 
Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate 
inflammation in vivo. J Immunol, 186(11), 6585-6596. 
doi:10.4049/jimmunol.1002794 
 
23. Harris, A., Torres-Viera, C., Venkataraman, L., DeGirolami, P., Samore, M., & 
Carmeli, Y. (1999). Epidemiology and clinical outcomes of patients with 
multiresistant Pseudomonas aeruginosa. Clin Infect Dis, 28(5), 1128-1133. 
doi:10.1086/514760 
 
24. Ogston, A. (1881). Report upon Micro-Organisms in Surgical Diseases. Br Med 
J, 1(1054), 369.b362-375.  
 
25. Eriksen, N. H. R. E., F.; Rosdahl, V. T.; Jensen, K. (1995). Carriage of 
Staphylococcus aureus among 104 Healthy Persons during a 19-Month Period. 
Epidemiol Infect, 115(1).  
 
26. Akobi, B., Aboderin, O., Sasaki, T., & Shittu, A. (2012). Characterization of 
Staphylococcus aureus isolates from faecal samples of the Straw-Coloured Fruit 
Bat (Eidolon helvum) in Obafemi Awolowo University (OAU), Nigeria. BMC 
Microbiol, 12, 279. doi:10.1186/1471-2180-12-279 
 
27. Espinosa-Gongora, C., Chrobak, D., Moodley, A., Bertelsen, M. F., & 
Guardabassi, L. (2012). Occurrence and distribution of Staphylococcus aureus 
lineages among zoo animals. Vet Microbiol, 158(1-2), 228-231. 
doi:10.1016/j.vetmic.2012.01.027 
 
28. Faires, M. C., Gehring, E., Mergl, J., & Weese, J. S. (2009). Methicillin-
resistant Staphylococcus aureus in marine mammals. Emerg Infect Dis, 15(12), 
2071-2072. doi:10.3201/eid1512.090220 
 
29. Gomez, P., Gonzalez-Barrio, D., Benito, D., Garcia, J. T., Vinuela, J., Zarazaga, 
M., . . . Torres, C. (2014). Detection of methicillin-resistant Staphylococcus 
aureus (MRSA) carrying the mecC gene in wild small mammals in Spain. J 
Antimicrob Chemother, 69(8), 2061-2064. doi:10.1093/jac/dku100 
 
30. Lowe, B. A., Marsh, T. L., Isaacs-Cosgrove, N., Kirkwood, R. N., Kiupel, M., 
& Mulks, M. H. (2011). Microbial communities in the tonsils of healthy pigs. 
Vet Microbiol, 147(3-4), 346-357. doi:10.1016/j.vetmic.2010.06.025 
 
31. Morris, P. J., Johnson, W. R., Pisani, J., Bossart, G. D., Adams, J., Reif, J. S., & 
Fair, P. A. (2011). Isolation of culturable microorganisms from free-ranging 
bottlenose dolphins (Tursiops truncatus) from the southeastern United States. 
Vet Microbiol, 148(2-4), 440-447. doi:10.1016/j.vetmic.2010.08.025 
 
 54 
32. Nowakiewicz, A., Zieba, P., Ziolkowska, G., Gnat, S., Muszynska, M., 
Tomczuk, K., . . . Troscianczyk, A. (2016). Free-Living Species of Carnivorous 
Mammals in Poland: Red Fox, Beech Marten, and Raccoon as a Potential 
Reservoir of Salmonella, Yersinia, Listeria spp. and Coagulase-Positive 
Staphylococcus. PLoS ONE, 11(5), e0155533. 
doi:10.1371/journal.pone.0155533 
 
33. van Elk, C. E., Boelens, H. A., van Belkum, A., Foster, G., & Kuiken, T. 
(2012). Indications for both host-specific and introduced genotypes of 
Staphylococcus aureus in marine mammals. Vet Microbiol, 156(3-4), 343-346. 
doi:10.1016/j.vetmic.2011.10.034 
 
34. Kuroda, M. O., T; Uchiyama I; et al. (2001). Whole genome sequencing of 
meticillin-resistant Staphylococcus aureus. Lancet, 357, 1225-1240.  
 
35. Fowler, V. G., Jr., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, 
E., . . . Bayer, A. S. (2005). Staphylococcus aureus endocarditis: a consequence 
of medical progress. Jama, 293(24), 3012-3021. doi:10.1001/jama.293.24.3012 
 
36. Inoue, S., Moriyama, T., Horinouchi, Y., Tachibana, T., Okada, F., Maruo, K., 
& Yoshiya, S. (2013). Comparison of clinical features and outcomes of 
Staphylococcus aureus vertebral osteomyelitis caused by methicillin-resistant 
and methicillin-sensitive strains. Springerplus, 2(1), 283. doi:10.1186/2193-
1801-2-283 
 
37. Gillet, Y., Issartel, B., Vanhems, P., Fournet, J. C., Lina, G., Bes, M., . . . 
Etienne, J. (2002). Association between Staphylococcus aureus strains carrying 
gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia 
in young immunocompetent patients. Lancet, 359(9308), 753-759. 
doi:10.1016/s0140-6736(02)07877-7 
 
38. Murdoch, D. R., Roberts, S. A., Fowler Jr, V. G., Jr., Shah, M. A., Taylor, S. L., 
Morris, A. J., & Corey, G. R. (2001). Infection of orthopedic prostheses after 
Staphylococcus aureus bacteremia. Clin Infect Dis, 32(4), 647-649. 
doi:10.1086/318704 
 
39. Tsukayama, D. T., Wicklund, B., & Gustilo, R. B. (1991). Suppressive 
antibiotic therapy in chronic prosthetic joint infections. Orthopedics, 14(8), 841-
844.  
 
40. Nielsen, J., Ladefoged, S. D., & Kolmos, H. J. (1998). Dialysis catheter-related 
septicaemia--focus on Staphylococcus aureus septicaemia. Nephrol Dial 
Transplant, 13(11), 2847-2852.  
 
41. Mohan, S. S., McDermott, B. P., & Cunha, B. A. (2005). Methicillin-resistant 
Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular 
 55 
abscess treated with daptomycin. Heart Lung, 34(1), 69-71. 
doi:10.1016/j.hrtlng.2004.07.009 
 
42. Chamis, A. L., Peterson, G. E., Cabell, C. H., Corey, G. R., Sorrentino, R. A., 
Greenfield, R. A., . . . Fowler, V. G., Jr. (2001). Staphylococcus aureus 
bacteremia in patients with permanent pacemakers or implantable cardioverter-
defibrillators. Circulation, 104(9), 1029-1033.  
 
43. Ahn, C. Y., Ko, C. Y., Wagar, E. A., Wong, R. S., & Shaw, W. W. (1996). 
Microbial evaluation: 139 implants removed from symptomatic patients. Plast 
Reconstr Surg, 98(7), 1225-1229.  
 
44. McCaig, L. F., McDonald, L. C., Mandal, S., & Jernigan, D. B. (2006). 
Staphylococcus aureus-associated skin and soft tissue infections in ambulatory 
care. Emerg Infect Dis, 12(11), 1715-1723. doi:10.3201/eid1211.060190 
 
45. Miethke, T., Gaus, H., Wahl, C., Heeg, K., & Wagner, H. (1992). T-cell-
dependent shock induced by a bacterial superantigen. Chem Immunol, 55, 172-
184.  
 
46. Kitai, S., Shimizu, A., Kawano, J., Sato, E., Nakano, C., Uji, T., & Kitagawa, H. 
(2005). Characterization of methicillin-resistant Staphylococcus aureus isolated 
from retail raw chicken meat in Japan. J Vet Med Sci, 67(1), 107-110.  
 
47. Syne, S. M., Ramsubhag, A., & Adesiyun, A. A. (2013). Microbiological hazard 
analysis of ready-to-eat meats processed at a food plant in Trinidad, West 
Indies. Infect Ecol Epidemiol, 3. doi:10.3402/iee.v3i0.20450 
 
48. Crass, B. A., & Bergdoll, M. S. (1986). Toxin involvement in toxic shock 
syndrome. J Infect Dis, 153(5), 918-926.  
 
49. Staali, L. M., H.; Colin, D.A. (1998). The Staphylococcal Pore-forming 
Leukotoxins Open Ca2+ Channels in the Membrane of Human 
Polymorphonuclear Neutrophils. J Membr Biol, 162(3), 209-216. 
doi:10.1007/s002329900358 
 
50. Kaneko, J., Ozawa, T., Tomita, T., & Kamio, Y. (1997). Sequential binding of 
Staphylococcal gamma-hemolysin to human erythrocytes and complex 
formation of the hemolysin on the cell surface. Biosci Biotechnol Biochem, 
61(5), 846-851. doi:10.1271/bbb.61.846 
 
51. Sugawara, T., Yamashita, D., Kato, K., Peng, Z., Ueda, J., Kaneko, J., . . . Yao, 
M. (2015). Structural basis for pore-forming mechanism of staphylococcal 
alpha-hemolysin. Toxicon, 108, 226-231. doi:10.1016/j.toxicon.2015.09.033 
 
 56 
52. Bantel, H., Sinha, B., Domschke, W., Peters, G., Schulze-Osthoff, K., & 
Janicke, R. U. (2001). alpha-Toxin is a mediator of Staphylococcus aureus-
induced cell death and activates caspases via the intrinsic death pathway 
independently of death receptor signaling. J Cell Biol, 155(4), 637-648. 
doi:10.1083/jcb.200105081 
 
53. Fowler, T. W., E. R.; Joh, D.; Johansson, S.; Foster, T. J.; Hook, M. (2000). 
Cellular invasion by Staphylococcus aureus involves a fibronectin bridge 
between the bacterial fibronectin-bidning MSCRAMMs and the host cell B1 
integrins. Eur J Cell Biol, 79(10), 672-679. doi:10.1078/0171-9335-00104 
 
54. Peacock, S. J. D., N. P. J.; Thomas, M. G.; Berendt, A. R.; Foster, T. J. (2000). 
Clinical Isolates of Staphylococcus aureus Exhibit Diversity in fnb Genes and 
Adhesion to Human Fibronectin. J Infect, 41(1), 23-31. 
doi:10.1053/jinf.2000.0657 
 
55. Mazmanian, S. K. L., G.; Ton-That, H.; Schneewind, O. (1999). Staphylococcus 
aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science, 
285(5428), 760-763.  
 
56. Ghasemian, A. P., S. N., Bakhshi, B.; Mirzaee, M. (2015). The Microbial 
Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) 
Genes among Clinical Isolates of Staphylococcus aureus from Hospitalized 
Children. Iran J Path, 10(4), 258-264.  
 
57. Heilmann, C. N., S.; Sinha, B.; Herrman, M; Kehrel B. E.; Peters, G. (2004). 
Staphylococcus aureus fibronectin-binding protein (FnBP)-mediated adherence 
to platelets, and aggregation of platelets induced by FnBPA but not by FnBPB. 
J Infect Dis, 190(2), 321-329. doi:10.1086/421914 
 
58. Schneewind, O., ; Model, P.; Fischetti, V. A. (1992). Sorting of protein A to the 
staphylococcal cell wall. Cell, 70(2), 267-281.  
 
59. Walsh, E. J. M., H.; Gorkun, O. V.; Foster, T. J. (2008). Identification of the 
Staphylococcus aureus MSCRAMM clumping factor B (ClfB) binding site in 
the αC-domain of human fibrinogen. Microbiology, 154(2), 550-558. 
doi:10.1099/mic.0.2007/010868-0 
 
60. Forsgren, A. S., J. (1966). "Protein A" from S. aureus. I. Pseudo-immune 
reaction with human gamma-globulin. J Immunol, 97(6), 822-827.  
 
61. Forsgren, A. Q., P.G. (1974). Effects of Staphylococcal Protein a on Heat Labile 
Opsonins. J Immunol, 112(3), 1177-1180.  
 
 57 
62. Cramton, S. E., Gerke, C., Schnell, N. F., Nichols, W. W., & Gotz, F. (1999). 
The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is 
required for biofilm formation. Infect Immun, 67(10), 5427-5433.  
 
63. Goss, C. H., & Muhlebach, M. S. (2011). Review: Staphylococcus aureus and 
MRSA in cystic fibrosis. J Cyst Fibros, 10(5), 298-306. 
doi:10.1016/j.jcf.2011.06.002 
 
64. Rolinson, G. N., Stevens, S., Batchelor, F. R., Wood, J. C., & Chain, E. B. 
(1960). Bacteriological studies on a new penicillin-BRL. 1241. Lancet, 2(7150), 
564-567.  
 
65. Ubukata, K., Nonoguchi, R., Matsuhashi, M., & Konno, M. (1989). Expression 
and inducibility in Staphylococcus aureus of the mecA gene, which encodes a 
methicillin-resistant S. aureus-specific penicillin-binding protein. J Bacteriol, 
171(5), 2882-2885.  
 
66. Bloemendaal, A. L., Brouwer, E. C., & Fluit, A. C. (2010). Methicillin 
resistance transfer from Staphylocccus epidermidis to methicillin-susceptible 
Staphylococcus aureus in a patient during antibiotic therapy. PLoS One, 5(7), 
e11841. doi:10.1371/journal.pone.0011841 
 
67. Apellaniz, G., Valdes, M., Perez, R., Martin, F., Soria, F., Garcia, A., . . . 
Vicente, T. (1991). Comparison of the effectiveness of various antibiotics in the 
treatment of methicillin-susceptible Staphylococcus aureus experimental 
infective endocarditis. J Chemother, 3(2), 91-97.  
 
68. Cantoni, L., Wenger, A., Glauser, M. P., & Bille, J. (1989). Comparative 
efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against 
methicillin-sensitive and methicillin-resistant Staphylococcus aureus 
endocarditis in rats. J Infect Dis, 159(5), 989-993.  
 
69. Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., 
Downes, F. P., . . . Fridkin, S. K. (2003). Infection with vancomycin-resistant 
Staphylococcus aureus containing the vanA resistance gene. N Engl J Med, 
348(14), 1342-1347. doi:10.1056/NEJMoa025025 
 
70. Razvi, S., Quittell, L., Sewall, A., Quinton, H., Marshall, B., & Saiman, L. 
(2009). Respiratory microbiology of patients with cystic fibrosis in the United 
States, 1995 to 2005. Chest, 136(6), 1554-1560. doi:10.1378/chest.09-0132 
 
71. Rasolomampianina, R., Bailly, X., Fetiarison, R., Rabevohitra, R., Bena, G., 
Ramaroson, L., . . . Avarre, J. C. (2005). Nitrogen-fixing nodules from rose 
wood legume trees (Dalbergia spp.) endemic to Madagascar host seven 




72. Hubner, A., Danganan, C. E., Xun, L., Chakrabarty, A. M., & Hendrickson, W. 
(1998). Genes for 2,4,5-trichlorophenoxyacetic acid metabolism in 
Burkholderia cepacia AC1100: characterization of the tftC and tftD genes and 
locations of the tft operons on multiple replicons. Appl Environ Microbiol, 
64(6), 2086-2093.  
 
73. Folsom, B. R., Chapman, P. J., & Pritchard, P. H. (1990). Phenol and 
trichloroethylene degradation by Pseudomonas cepacia G4: kinetics and 
interactions between substrates. Appl Environ Microbiol, 56(5), 1279-1285.  
 
74. Schmidt, S., Blom, J. F., Pernthaler, J., Berg, G., Baldwin, A., 
Mahenthiralingam, E., & Eberl, L. (2009). Production of the antifungal 
compound pyrrolnitrin is quorum sensing-regulated in members of the 
Burkholderia cepacia complex. Environ Microbiol, 11(6), 1422-1437. 
doi:10.1111/j.1462-2920.2009.01870.x 
 
75. Jacobs, J. L., Fasi, A. C., Ramette, A., Smith, J. J., Hammerschmidt, R., & 
Sundin, G. W. (2008). Identification and onion pathogenicity of Burkholderia 
cepacia complex isolates from the onion rhizosphere and onion field soil. Appl 
Environ Microbiol, 74(10), 3121-3129.  
 
76. Blattner, F. R., Plunkett, G., 3rd, Bloch, C. A., Perna, N. T., Burland, V., Riley, 
M., . . . Shao, Y. (1997). The complete genome sequence of Escherichia coli K-
12. Science, 277(5331), 1453-1462.  
 
77. Holden, M. T., Seth-Smith, H. M., Crossman, L. C., Sebaihia, M., Bentley, S. 
D., Cerdeno-Tarraga, A. M., . . . Parkhill, J. (2009). The genome of 
Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis 
patients. J Bacteriol, 191(1), 261-277. doi:10.1128/JB.01230-08 
 
78. Laraya-Cuasay, L. L., M.; Huang, N. N. (1977). Pseudomonas cepacia in the 
respiratory flora of patients with cystic fibrosis (CF). Pediatr. Res., 11, 502.  
 
79. Johnson, W. M., Tyler, S. D., & Rozee, K. R. (1994). Linkage analysis of 
geographic and clinical clusters in Pseudomonas cepacia infections by 
multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol, 32(4), 924-
930.  
 
80. LiPuma, J. J., Spilker, T., Gill, L. H., Campbell, P. W., 3rd, Liu, L., & 
Mahenthiralingam, E. (2001). Disproportionate distribution of Burkholderia 
cepacia complex species and transmissibility markers in cystic fibrosis. Am J 
Respir Crit Care Med, 164(1), 92-96. doi:10.1164/ajrccm.164.1.2011153 
 
 59 
81. De Boeck, K., Malfroot, A., Van Schil, L., Lebecque, P., Knoop, C., Govan, J. 
R., . . . Vandamme, P. (2004). Epidemiology of Burkholderia cepacia complex 
colonisation in cystic fibrosis patients. Eur Respir J, 23(6), 851-856.  
 
82. Vandamme, P., Holmes, B., Coenye, T., Goris, J., Mahenthiralingam, E., 
LiPuma, J. J., & Govan, J. R. (2003). Burkholderia cenocepacia sp. nov.--a new 
twist to an old story. Res Microbiol, 154(2), 91-96. doi:10.1016/S0923-
2508(03)00026-3 
 
83. Coenye, T., & LiPuma, J. J. (2002). Multilocus restriction typing: a novel tool 
for studying global epidemiology of Burkholderia cepacia complex infection in 
cystic fibrosis. J Infect Dis, 185(10), 1454-1462. doi:10.1086/340279 
 
84. Sajjan, U. S., Corey, M., Karmali, M. A., & Forstner, J. F. (1992). Binding of 
Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin 
from patients with cystic fibrosis. J Clin Invest, 89(2), 648-656.  
 
85. Sajjan, U. S., & Forstner, J. F. (1993). Role of a 22-kilodalton pilin protein in 
binding of Pseudomonas cepacia to buccal epithelial cells. Infect Immun, 61(8), 
3157-3163.  
 
86. Mahenthiralingam, E., Vandamme, P., Campbell, M. E., Henry, D. A., Gravelle, 
A. M., Wong, L. T., . . . Speert, D. P. (2001). Infection with Burkholderia 
cepacia complex genomovars in patients with cystic fibrosis: virulent 
transmissible strains of genomovar III can replace Burkholderia multivorans. 
Clin Infect Dis, 33(9), 1469-1475.  
 
87. van Schaik, E. J., Giltner, C. L., Audette, G. F., Keizer, D. W., Bautista, D. L., 
Slupsky, C. M., . . . Irvin, R. T. (2005). DNA binding: a novel function of 
Pseudomonas aeruginosa type IV pili. J Bacteriol, 187(4), 1455-1464. 
doi:10.1128/jb.187.4.1455-1464.2005 
 
88. Lamothe, J., Huynh, K. K., Grinstein, S., & Valvano, M. A. (2007). Intracellular 
survival of Burkholderia cenocepacia in macrophages is associated with a delay 
in the maturation of bacteria-containing vacuoles. Cell Microbiol, 9(1), 40-53.  
 
89. Sajjan, S. U., Carmody, L. A., Gonzalez, C. F., & LiPuma, J. J. (2008). A type 
IV secretion system contributes to intracellular survival and replication of 
Burkholderia cenocepacia. Infect Immun, 76(12), 5447-5455. 
doi:10.1128/IAI.00451-08 
 
90. Rosales-Reyes, R., Skeldon, A. M., Aubert, D. F., & Valvano, M. A. (2012). 
The Type VI secretion system of Burkholderia cenocepacia affects multiple 
Rho family GTPases disrupting the actin cytoskeleton and the assembly of 




91. LiPuma, J. J., Dasen, S. E., Nielson, D. W., Stern, R. C., & Stull, T. L. (1990). 
Person-to-person transmission of Pseudomonas cepacia between patients with 
cystic fibrosis. Lancet, 336(8723), 1094-1096.  
 
92. Isles, A., Maclusky, I., Corey, M., Gold, R., Prober, C., Fleming, P., & Levison, 
H. (1984). Pseudomonas cepacia infection in cystic fibrosis: an emerging 
problem. J Pediatr, 104(2), 206-210.  
 
93. Singh, P. K., Schaefer, A. L., Parsek, M. R., Moninger, T. O., Welsh, M. J., & 
Greenberg, E. P. (2000). Quorum-sensing signals indicate that cystic fibrosis 
lungs are infected with bacterial biofilms. Nature, 407(6805), 762-764. 
doi:10.1038/35037627 
 
94. Klausen, M., Aaes-Jorgensen, A., Molin, S., & Tolker-Nielsen, T. (2003). 
Involvement of bacterial migration in the development of complex multicellular 
structures in Pseudomonas aeruginosa biofilms. Mol Microbiol, 50(1), 61-68.  
 
95. Guggenheim, M., Shapiro, S., Gmur, R., & Guggenheim, B. (2001). Spatial 
arrangements and associative behavior of species in an in vitro oral biofilm 
model. Appl Environ Microbiol, 67(3), 1343-1350. doi:10.1128/aem.67.3.1343-
1350.2001 
 
96. Nijland, R., Hall, M. J., & Burgess, J. G. (2010). Dispersal of biofilms by 
secreted, matrix degrading, bacterial DNase. PLoS One, 5(12), e15668. 
doi:10.1371/journal.pone.0015668 
 
97. Anwar, H., & Costerton, J. W. (1990). Enhanced activity of combination of 
tobramycin and piperacillin for eradication of sessile biofilm cells of 
Pseudomonas aeruginosa. Antimicrob Agents Chemother, 34(9), 1666-1671.  
 
98. Moskowitz, S. M., Foster, J. M., Emerson, J., & Burns, J. L. (2004). Clinically 
feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa 
from patients with cystic fibrosis. J Clin Microbiol, 42(5), 1915-1922.  
 
99. Thurlow, L. R., Hanke, M. L., Fritz, T., Angle, A., Aldrich, A., Williams, S. H., 
. . . Kielian, T. (2011). Staphylococcus aureus biofilms prevent macrophage 
phagocytosis and attenuate inflammation in vivo. J Immunol, 186(11), 6585-
6596. doi:10.4049/jimmunol.1002794 
 
100. Schommer, N. N., Christner, M., Hentschke, M., Ruckdeschel, K., 
Aepfelbacher, M., & Rohde, H. (2011). Staphylococcus epidermidis uses 
distinct mechanisms of biofilm formation to interfere with phagocytosis and 




101. Burmolle, M., Webb, J. S., Rao, D., Hansen, L. H., Sorensen, S. J., & 
Kjelleberg, S. (2006). Enhanced biofilm formation and increased resistance to 
antimicrobial agents and bacterial invasion are caused by synergistic 
interactions in multispecies biofilms. Appl Environ Microbiol, 72(6), 3916-
3923. doi:10.1128/aem.03022-05 
 
102. Lee, K. W., Periasamy, S., Mukherjee, M., Xie, C., Kjelleberg, S., & Rice, S. A. 
(2014). Biofilm development and enhanced stress resistance of a model, mixed-
species community biofilm. Isme j, 8(4), 894-907. doi:10.1038/ismej.2013.194 
 
103. Burns, J. L. E., J.; Stapp, J. R.; Yim, D. L.; Krzewinski, J.; Louden, L.; Ramsey, 
B. W.; Clausen, C. R. (1998). Microbiology of Sputum from Patients at Cystic 
Fibrosis Centers in the United States. Clin Infect Dis, 27(1), 158-163.  
 
104. Lam, J., Chan, R., Lam, K., & Costerton, J. W. (1980). Production of mucoid 
microcolonies by Pseudomonas aeruginosa within infected lungs in cystic 
fibrosis. Infect Immun, 28(2), 546-556.  
 
105. Tom, S. K., Yau, Y. C., Beaudoin, T., LiPuma, J. J., & Waters, V. (2015). 
Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter 
Species Isolated from Cystic Fibrosis Patients. Antimicrob Agents Chemother, 
60(1), 650-652. doi:10.1128/aac.02240-15 
 
106. Schwab, U., Abdullah, L. H., Perlmutt, O. S., Albert, D., Davis, C. W., Arnold, 
R. R., . . . Boucher, R. C. (2014). Localization of Burkholderia cepacia complex 
bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa 
in hypoxic mucus. Infect Immun, 82(11), 4729-4745. doi:10.1128/iai.01876-14 
 
107. Vuong, C., Saenz, H. L., Gotz, F., & Otto, M. (2000). Impact of the agr 
quorum-sensing system on adherence to polystyrene in Staphylococcus aureus. 
J Infect Dis, 182(6), 1688-1693. doi:10.1086/317606 
 
108. Di Bonaventura, G., Stepanovic, S., Picciani, C., Pompilio, A., & Piccolomini, 
R. (2007). Effect of environmental factors on biofilm formation by clinical 
Stenotrophomonas maltophilia isolates. Folia Microbiol (Praha), 52(1), 86-90.  
 
109. Hoiby, N., Ciofu, O., & Bjarnsholt, T. (2010). Pseudomonas aeruginosa 
biofilms in cystic fibrosis. Future Microbiol, 5(11), 1663-1674. 
doi:10.2217/fmb.10.125 
 
110. Whiteley, M., Bangera, M. G., Bumgarner, R. E., Parsek, M. R., Teitzel, G. M., 
Lory, S., & Greenberg, E. P. (2001). Gene expression in Pseudomonas 
aeruginosa biofilms. Nature, 413(6858), 860-864. doi:10.1038/35101627 
 
111. Ryan, R. P., Fouhy, Y., Garcia, B. F., Watt, S. A., Niehaus, K., Yang, L., . . . 
Dow, J. M. (2008). Interspecies signalling via the Stenotrophomonas 
 62 
maltophilia diffusible signal factor influences biofilm formation and polymyxin 
tolerance in Pseudomonas aeruginosa. Mol Microbiol, 68(1), 75-86. 
doi:10.1111/j.1365-2958.2008.06132.x 
 
112. Tomlin, K. L., Coll, O. P., & Ceri, H. (2001). Interspecies biofilms of 
Pseudomonas aeruginosa and Burkholderia cepacia. Can J Microbiol, 47(10), 
949-954.  
 
113. Yang, L., Liu, Y., Markussen, T., Hoiby, N., Tolker-Nielsen, T., & Molin, S. 
(2011). Pattern differentiation in co-culture biofilms formed by Staphylococcus 
aureus and Pseudomonas aeruginosa. FEMS Immunol Med Microbiol, 62(3), 
339-347. doi:10.1111/j.1574-695X.2011.00820.x 
 
114. O'Toole, G. A. (2011). Microtiter dish biofilm formation assay. J Vis Exp(47). 
doi:10.3791/2437 
 
115. Harrison, J. J., Stremick, C. A., Turner, R. J., Allan, N. D., Olson, M. E., & 
Ceri, H. (2010). Microtiter susceptibility testing of microbes growing on peg 
lids: a miniaturized biofilm model for high-throughput screening. Nat Protoc, 
5(7), 1236-1254. doi:10.1038/nprot.2010.71 
 
116. Dubbary, N.; Du, W.; Lane, D.; Pasta, F. (2009). Improved 
Electrotransformation and Decreased Antibiotic Resistance of the Cystic 
Fibrosis Pathogen Burkholderia cenocepacia Strain J2315. Appl Environ 
Microbiol, 74(4), 1095-1102. doi: 10.1128/AEM.02123-09 
 
117. Tang, X. X., Ostedgaard, L. S., Hoegger, M. J., Moninger, T. O., Karp, P. H., 
McMenimen, J. D., . . . Welsh, M. J. (2016). Acidic pH increases airway surface 
liquid viscosity in cystic fibrosis. J Clin Invest, 126(3), 879-891. 
doi:10.1172/jci83922 
 
118. Foulston, L., Elsholz, A. K., DeFrancesco, A. S., & Losick, R. (2014). The 
extracellular matrix of Staphylococcus aureus biofilms comprises cytoplasmic 
proteins that associate with the cell surface in response to decreasing pH. MBio, 
5(5), e01667-01614. doi:10.1128/mBio.01667-14 
 
119. Sugimoto, S., Iwamoto, T., Takada, K., Okuda, K., Tajima, A., Iwase, T., & 
Mizunoe, Y. (2013). Staphylococcus epidermidis Esp degrades specific proteins 
associated with Staphylococcus aureus biofilm formation and host-pathogen 
interaction. J Bacteriol, 195(8), 1645-1655. doi:10.1128/jb.01672-12 
 
120. Van Acker, H., Gielis, J., Acke, M., Cools, F., Cos, P., & Coenye, T. (2016). 
The Role of Reactive Oxygen Species in Antibiotic-Induced Cell Death in 




121. Haba, E., Pinazo, A., Jauregui, O., Espuny, M. J., Infante, M. R., & Manresa, A. 
(2003). Physicochemical characterization and antimicrobial properties of 
rhamnolipids produced by Pseudomonas aeruginosa 47T2 NCBIM 40044. 
Biotechnol Bioeng, 81(3), 316-322. doi:10.1002/bit.10474 
 
122. Davey, M. E., Caiazza, N. C., & O'Toole, G. A. (2003). Rhamnolipid surfactant 
production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J 
Bacteriol, 185(3), 1027-1036.  
 
123. Bartell, J. A., Yen, P., Varga, J. J., Goldberg, J. B., & Papin, J. A. (2014). 
Comparative metabolic systems analysis of pathogenic Burkholderia. J 
Bacteriol, 196(2), 210-226. doi:10.1128/jb.00997-13 
 
124. Hutchison, M. L., Poxton, I. R., & Govan, J. R. (1998). Burkholderia cepacia 
produces a hemolysin that is capable of inducing apoptosis and degranulation of 
mammalian phagocytes. Infect Immun, 66(5), 2033-2039.  
 
125. Mashburn, L. M., Jett, A. M., Akins, D. R., & Whiteley, M. (2005). 
Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa 
during in vivo coculture. J Bacteriol, 187(2), 554-566. 
doi:10.1128/JB.187.2.554-566.2005 
 
126. Darling, P., Chan, M., Cox, A. D., & Sokol, P. A. (1998). Siderophore 
production by cystic fibrosis isolates of Burkholderia cepacia. Infect Immun, 
66(2), 874-877.  
 
127. Sokol, P. A., Darling, P., Lewenza, S., Corbett, C. R., & Kooi, C. D. (2000). 
Identification of a siderophore receptor required for ferric ornibactin uptake in 
Burkholderia cepacia. Infect Immun, 68(12), 6554-6560.  
 
128. Sokol, P. A., Darling, P., Woods, D. E., Mahenthiralingam, E., & Kooi, C. 
(1999). Role of ornibactin biosynthesis in the virulence of Burkholderia 
cepacia: characterization of pvdA, the gene encoding L-ornithine N(5)-
oxygenase. Infect Immun, 67(9), 4443-4455.  
 
129. Visser, M. B., Majumdar, S., Hani, E., & Sokol, P. A. (2004). Importance of the 
ornibactin and pyochelin siderophore transport systems in Burkholderia 
cenocepacia lung infections. Infect Immun, 72(5), 2850-2857.  
 
130. Rayner, C., & Munckhof, W. J. (2005). Antibiotics currently used in the 
treatment of infections caused by Staphylococcus aureus. Intern Med J, 35 
















I. Supplementary Table 

































































Supplementary Table 1. Description of incubation times and colony 












Strain Colony Morphology Incubation Time 
A. xylosoxidans 
AU19284 
Small colonies, white 48 h 
P. aeruginosa C3719 Large colonies, tinged pink 24-48 h 
S. maltophilia K279a 
Largest colonies, dark 
yellow 
24h 
S. aureus NRS77 Large colonies, white 24 h 
B. cenocepacia J2315 
Smallest colonies, tan, 
produce a brown pigment 



















Supplementary Figure 1. Co-culture biofilm formation of common CF pathogens. Viable 
cell counts of A. xylosoxidans AU19284 (A), S. maltophilia K279a (B), and P. aeruginosa C3719 
(C) biofilm grown were compared when grown in with A. xylosoxidans (red), P. aeruginosa 
C3719 (orange), S. maltophilia K279a (green), S. aureus NRS77 (blue), or B. cenocepacia J2315 
(purple). Presence of “X” indicates contamination, and therefore exclusion of data. Absence of a 
bar indicates the CFU/mL is below the limit of detection, which was 105 for this experiment. 
One-way ANOVA analysis with Tukey’s multiple comparison test was used to determine 
significance (*p < 0.05, **p < 0.01). 
 
The ability of S. maltophilia K279a to form biofilm was not affected by the 
presence of the tested strains. There was no significant difference in S. maltophilia K279a 
biofilm formation in monoculture compared to co-culture conditions on both day one and 
day three of biofilm formation. On the other hand, the presence of S. maltophilia K279a 
in co-culture reduced biofilm formation below the limit of detection in both A. 
xylosoxidans AU19284 and P. aeruginosa C3719. The biofilm formation of A. 
xylosoxidans AU19284 in co-culture with B. cenocepacia J2315 was significantly greater 
than monoculture on day one, but was significantly lower than monoculture on day three. 
Interestingly, the presence of S. aureus NRS77 significantly inhibits A. xylosoxidans 
AU19284 biofilm formation on day one, and reduces biofilm below the limit of detection 
on day three. P. aeruginosa  C3719 biofilm was significantly increased due to the 
presence of B. cenocepacia J2315 on day one, but biofilm formation on day three in this 
co-culture condition was not statistically significant in comparison to monoculture.  
Repeated experimentation over a longer period of time or with a lower limit of detection 
would further elucidate the interactions between some of these isolates in co-culture 
conditions. 
